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1. Introduction 
The macula is a round highly pigmented yellow spot 
at the center of the posterior pole, it specialized for 
high acuity vision and it is important for reading, 
writing, driving, working on the computer and for 
trips (American Academy of ophthalmology, 2011). 
Macular edema (ME) is the most common pathology 
of the macula, which is the main cause of 
impairment of central vision. Diseases such as 
diabetic macular edema (DME), age-related 
macular degeneration (ARMD) retinal vascular 
occlusive diseases, and vitreoretinal interface 
disorders are the most frequent reasons of ME. For 
more than 30 years, physicians have been trying to 
identify the macular edema in its initial state and to 
define their different etiologies (Nussenblat RB et al., 
1987). 
Since 2004, the clinical diagnosis of macular 
diseases and its treatment have been greatly 
improved due to remarkable advances of modern 
imaging technologies, such as Spectralis optical 
coherence tomography (OCT) that has a valuable 
technique for the detection, evaluation and 
monitoring the central retinal thickness 
measurement (CRT) in macular diseases (Wotjkowski 
M, Srinivasan et al., 2005; Alam S, Zawadzki RJ, Choi S, et al., 
2006). 
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One of the most important innovations in the field of 
macular diseases has been the introduction of 
intravitreal drug delivery approaches for the 
treatment of posterior segment pathologies. These 
emerging modalities restore the permeability of the 
blood-retinal barrier by delivering drug compounds 
intravitreally with anti-inflammatory or anti-vascular 
endothelial growth factor drugs (Anti-VEGF). 
Even though the morphological findings of the 
macular pathologies are known, the interpretation 
and measurements of them by OCT may vary. 
Some of these factors are; the quality of the 
captured images, the type of the OCT machine, the 
experience of the physician and at lastly the 
complexity of the findings.  
The purpose of this study is to determine the degree 
of agreement between a general ophthalmologist 
and a retina specialist in the diagnosis and 
classification of the CRT and morphological findings 
found by Spectralis OCT in macular diseases. The 
reliability between the observers and intraobserver 
will be analyzed by statistical methods. 
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1.1 Overview of the Macula 
 
The macula also called (macula lutea) is a round 
highly pigmented yellow spot at the posterior pole, 
lying inside the temporal vascular arcades; it has a 
diameter around 5 and 6mm, and subserves the 
central 15–20° of the visual field. This area contains 
a retinal pigment xanthophyll that confers 
hypofluorescence on angiography. 
The macular area is centered on the fovea, a small 
concave depression retinal about 1.5 mm in 
diameter where the photoreceptor layer is formed 
exclusively by cones which constitute 10% of the 
retinal cones. The foveal cones are specialized and 
have an especially high density. 
In the center of the fovea, there is the foveola, which 
is an avascular zone irrigated by the choriocapillaris. 
This part of the fovea does not contain inner nuclear 
layer and ganglion cell layer. The parafoveal area is 
a ring that is located 0.5 mm around the fovea. It is 
a region where the retina is thicker. The perifoveal 
area is a ring of 1.5 mm in diameter around the 
parafovea. 
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In the fovea there are 35,000 cones connecting with 
ganglion cells, so which is the area with the greatest 
capacity for visual discrimination of the retina 
(American Academy of ophthalmology, 2011) (Fig. 1). 
 
Fig. 1: Color photograph of the posterior pole. The anatomical fovea 
and foveola are in the center of the anatomical macula (by Spaide 
R.F. 2011).   
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1.2 Retinal Structures 
 
The retina is composed of ten distinct layers. These 
layers are dark nuclear layers, containing cell 
bodies, or light plexiform layers, containing axons 
and dendrites (Fig. 2).  
 
Fig. 2: Histological representation of the layers of the retina (by 
University of Bristol, Department of Anatomy 2000). 
The retina is a highly organized structure with 
common-path neuronal axons of ganglion cells, 
which leads the visual information to the brain. It 
has an average of 4.6 million cones and 92 million 
rods (American Academy of ophthalmology, 2011). 
The Internal limiting membrane (ILM) is the most 
superficial layer of the retina and is in contact with 
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the hyaloid of the vitreous gel. Histopathologically 
consists of the basement membrane of the 
extensions of the Müller cells. In the parafoveal and 
peripapillary region, the thickness of the ILM is 
about 2.5 microns. The side facing the vitreous 
cavity is thin, and the inside or retinal face is 
polished and irregular. 
The ILM can act as a basis for cell growth and 
proliferation. Frequently involved in disorders that 
affect the vitreomacular interface, including 
epiretinal membranes (ERM), vitreomacular traction 
syndrome (VMTS) and macular hole (MH). 
The inner third of the outer plexiform layer has a 
linear density where a synaptic connection between 
the photoreceptors and the processes of the bipolar 
cells occurs. 
The retinal pigment epithelium (RPE) is composed 
of a single layer of hexagonally shape cuboidal 
cells, lying between Bruch’s membrane and retina. 
These cells and the zonula occludentes constitute 
the outer blood retinal barrier, preventing 
extracellular fluid leaking into the subretinal space 
from the choriocapillaris, actively pump ions and 
water out of the subretinal space.  
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The central retinal artery and its branches, as well 
as the derivative venous return, are located in the 
inner retina, supplying nutrition to the inner nuclear 
layer. The nutritional value of the outer retina 
depends on the choriocapillaris, which is the 
innermost layer of the choroid that provides 
irrigation to the choroidal circulation. 
The vitreous cavity has a capacity of about 3-4 ml, 
which is 4/5 of the volume of the eyeball. The 
vitreous gel is tightly attached to the retina in the 
vitreous base, which extends to about 2-3 mm to the 
ora serrata. 
The posterior hyaloid is strongly attached to the 
optic nerve, retinal vessels, macula and some 
retinal scars (Yanoff M, Duker JS, 2008; American Academy of 
ophthalmology, 2011). 
 
1.3 History of Optical Coherence Tomography 
(OCT) 
In 1991, OCT was described by Huang and 
associates, as a non-invasive medical diagnostic 
imaging, which performs micrometer resolution 
cross-sectional or tomographic imaging of the tissue 
using low coherence interferometry (Huang D, Swanson 
EA, Lin CP et al. 1991).  
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In 1993, the first in vivo OCT-images (displaying 
retinal structures) were published (Fercher AF., 
Hitzenberger CK, Drexler W et al., 1993; Hee MR, Swanson EA, Izatt 
J et al., 1993).  
In 1995, time-domain optical coherence tomography 
(TD-OCT) was used for imaging macular diseases. 
Since then, OCT has become widely accepted for 
retinal thickness measurements and detection of the 
macular morphology in various retinal diseases 
(Puliafito CA, Hee MR, Lin CP et al., 1995). 
In 2002, TD-OCT 300 (Stratus OCT) became 
available with an axial resolution of 10 µm and a 
scan velocity of 400 axial scans per second (Drexler 
W, Sattmann H et al., 2003). 
Since 2004, higher-resolution spectral-domain OCT 
(SD-OCT) has entered clinical practice with reported 
resolutions of 1 to 5 µm as well as improved 
visualization of retinal morphologic and pathologic 
features. Today it is the current “gold standard” for 
posterior segment retinal tomography (Drexler W, 
Sattmann H et al., 2003; Wotjkowski M, Srinivasan et al., 2005; Alam 
S, Zawadzki RJ, Choi S et al., 2006). 
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1.4 Principles of OCT 
OCT is analogous to B-mode ultrasound, except 
that uses light rather that wave sound. Unlike 
ultrasound, OCT does not require contact with the 
tissue examined. OCT is based on an apical 
measurement technique known as a low coherence 
interferometry, which can be used to measure 
ocular structures with high precision by measuring 
the light reflected from them (Huang D, Swanson EA, Lin 
CP et al., 1991).  
In the OCT, a beam of light from a 
superluminescent diode is divided through a beam 
splitter into sample and reference beams (Fig. 3).  
Light from the sample beam is directed toward the 
tissue of interest. The light will be reflected with 
different echo time delays. Light from the reference 
beam is reflected from a different mirror located at a 
known distance. Both the reflected reference and 
sample beams are combined by a modified 
Michelson interferometer and detected by the OCT 
(Huang D, Swanson EA. Lin CP et al., 1991; Hee MR, Izatt JA, 
Swanson EA et al., 1995). 
Detection of these beams is based on time-domain 
or spectral-domain protocols. 
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Fig.3:  Principle of a Michelson interferometer type OCT system (by 
Jansz 2012). 
 
1.5 Time-domain OCT (TD-OCT) 
In TD-OCT, the position of the reference mirror is 
adjusted, creating different time delays for the 
echoes of the reference beam. Axial scans (A- 
scan) are obtained by directing the sample beam at 
different tissue depths and recording the reflected 
light echoes (Hee MR, Puliafito CA et al., 1995).   
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An example of TD-OCT is the Stratus-OCT, which 
has a resolution of <10 µm and can make from 128 
to 768 A-scan in a single scan pass. Each A-scan 
has 1,024 data points and is 2mm long. By scanning 
the sample beam of light in a transverse direction, a 
cross sectional OCT (B-scan) image is obtained. 
Once the information has been obtained, a 
tomography is constructed using a false color scale 
that represents the amount of light backscattering 
from microstructures at different depths of the 
imaged tissue.  
The images in TD-OCT are displayed in false color 
scale, bright colors such as red to white represent 
high reflectivity and dark colors such a blue to black 
represent minimal or no reflectivity (Hee MR, Puliafito CA 
et al., 1995) (Fig. 4).  
The ganglion cell layers (GCL), the inner nuclear 
layer (INL) and the outer nuclear layer (ONL) have a 
low reflectivity, and therefore appear blue-black in 
the false color scale. Conversely, the retinal pigment 
epithelium (RPE)/choriocapillaris and the retinal 
nerve fiber layer (RNFL), exhibit a high reflectivity 
(Toth CA, 1997). 
The hyper-reflective band at the level of the 
RPE/choriocapillaris is actually composed of two 
highly reflective lines separated from each other by 
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one thin layer of low to moderate reflectivity. The 
inner highly reflective line corresponds to the 
junction of the photoreceptor´s outer and inner 
segments (IS/OS). The outer highly reflective line 
corresponds to the RPE/choriocapillaris. 
Traditionally, the inner and outer retinal boundaries 
have been defined as the INL and RPE respectively 
(Costa RA et al., 2004; Pons ME et al., 2005; Sadda SR et al., 2007) 
(Fig. 4). 
 
Fig. 4: The time-domain Stratus OCT, the images are displayed in 
false color. High reflectivity structures are depicted as red, 
intermediate as green-yellow and low reflectivity as blue-black. High 
resolution OCT (B) has the ability to identify fine retinal structures 
such as the external limiting membrane and ganglion cell layer which 
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are not visualized as clearly with standard resolution (A). NFL: Nerve 
fiber layer, GCL: Ganglion cell layer, IPL: Inner plexiform layer, INL: 
Inner nuclear layer, OPL: Outer plexiform layer, ONL: Outer nuclear 
layer, ELM: External limiting membrane, IS/OS: Inner segment/outer 
segment junction, RPE: Retinal pigment epithelium (by Kanski J.  
2011).   
 
1.6 Limitations of TD-OCT 
EA Swanson et al. mentioned that although the time 
domain Stratus OCT achieved high resolution 
images of the eye; the image quality was limited by 
the speed of image acquisition (Fig. 4). Also 
mentioned that in each successive axial scan, the 
axial movement of the eyes of the patients became 
increasingly important in the quality and precision of 
the image factor. After image acquisition, digital 
processing could eliminate axial movement artifacts, 
however, it could also introduce errors in the 
topography of the retina (Swanson EA, Izatt JA, He MR et al., 
1993). Image acquisition speed also limited the total 
number of cross-sectional images. The movement 
of the eyes, dry tear film and blinking were 
contributing to poor quality images with higher 
image acquisition time. As a result, the TD-OCT 
retina coverage was limited. Focal pathologies could 
not be detected in a B-scan determined by OCT, 
leading to sampling errors. Moreover, since the 
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OCT B-scan was limited (Ray R, Stinnet SS, Jaffe GJ, 2005; 
Sadda SR et al., 2006). 
 
1.7 Spectral/Fourier–domain OCT (SD-OCT) 
SD-OCT detection represents an advance in OCT 
technology that enables imaging speeds of >25,000 
axial scans per second, or 50 times faster than TD-
OCT. Spectral or Fourier domain OCT is so named 
because the interference spectrum of echo time 
delays of light is measured by a spectrometer and 
high-speed charged-coupled device camera (Fercher 
AF et al., 1995; Wojtkowski M et al., 2002; Nassif NA et al., 2004; 
Leitgeb RA et al., 2004; Srinivasan J et al., 2006).  
Because the interference spectrum is composed of 
oscillations whose frequencies are proportional to 
the echo time delay, axial scan measurements can 
be obtained by calculating the Fourier transform. (A 
Fourier transform is a mathematical operation that 
extracts the frequency content of a signal). In 
contrast to TD detection, SD detection measures all 
echoes of light simultaneously, and the position of 
the reference arm does not need to be adjusted. 
The result is a significant improvement over time-
domain OCT in sensitivity and image acquisition 
speed (Chen TC, Cense B, 2005) (Fig. 5). 
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Fig.5:  Multiple spectral/Fourier–domain OCT. Note the spectrometer 
and the Fourier transform in SD-OCT (by Graf 2009). 
 
1.8 Limitations of SD-OCT 
The disadvantage of spectral/Fourier domain 
detection is that detection sensitivity and image 
resolution depend on imaging depth because of 
limitations on spectrometer resolution. 
 
1.9 Advantages of SD-OCT 
One of the main advantages of the SD-OCT is that 
with the increase in speed of image acquisition, 
motion artifacts are minimized, resulting in images 
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of higher quality and finer discrimination of 
intraretinal layers. SD-OCT has the ability to acquire 
a large number of cross-sectional images quickly to 
improve the coverage of the retina and also has the 
ability to allow multiple scan OCT cross sections to 
be taken on in a pattern of dense plot to cover a 
large area of the retina (Fig. 6). 
 
Fig.6: Comparison of TD to SD-OCT images. A normal macular scan 
acquired with SD-OCT (A). The same eye scanned with TD-OCT (B). 
Note the clear delineation of each retinal layer and the ability to 
clearly distinguish the inner segment/ outer segment junction of the 
photoreceptors from the retinal pigment epithelium in SD-OCT scans. 
NFL: Nerve fiber layer, GCL: Ganglion cell layer, IPL: Inner plexiform 
layer, INL: Inner nuclear layer, OPL: Outer plexiform layer, ONL: 
Outer nuclear layer, ELM: External limiting membrane, IS/OS: Inner 
segment/outer segment junction, RPE: Retinal pigment epithelium (by 
Yaqoob 2005).   
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1.10 Spectralis OCT 
Spectralis OCT (Heidelberg Engineering, 
Heidelberg, Germany), is the newer SD-OCT that 
uses a significantly faster, non-mechanical 
technology.  
Spectralis OCT measures simultaneously multiple 
wavelengths of reflected light across a spectrum, 
hence the name spectral domain. The system is 100 
times faster than TD-OCT and acquires 40,000 A-
scans per second with 5 µm optical, 3.9 µm digital 
axial resolution and 1.9mm scan depth. The 
increased speed and number of scans translates 
into higher resolution and a better chance of 
observing the diseases (Han IC, Jaffe GJ, 2009; Wolf-
Schnurrbusch et al., 2009) (Fig. 7).   
High speed image acquisition is combined with 
custom TruTrack technology to actively track the 
eye during imaging. Tracking eye movement with 
simultaneous dual-beam imaging minimizes motion 
artifact, enables noise reduction and allows the 
instrument to precisely track change over time. This 
real-time eye tracking enables a highly repeatable 
alignment of OCT and fundus images that can be 
displayed either in grayscale or false color and 
allows acquisition of 1 to 100 B-scans at the same 
location, facilitating removal of speckle noise 
artifact. The result is point to point correlation 
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between the fundus and OCT scans, greater image 
detail and clarity, and more confident assessment of 
small changes (Wolf-Schnurrbusch et al., 2009). 
 
Fig. 7: Example of a normal eye image with the Spectralis OCT high 
resolution. (ILM: internal limiting membrane; NFL: nerve fiber layer; 
GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear 
layer; OPL: outer plexiform layer; ONL: outer nuclear layer; ELM: 
external limiting membrane; IS/OS: photoreceptor inner/outer 
segment junction; RPE: retinal pigment epithelium, BM: Bruch 
membrane). 
 
1.11 OCT characteristics in Macula 
The OCT-image closely approximates the 
histological appearance of the macula and, for this 
reason, it has been referred to as an in vivo optical 
biopsy. When light travels through the retinal tissue 
it can be reflected, scattered, or absorbed, and this 
creates the multilayered pattern of the retina (Drexler 
W, Fujimoto JG, 2008). 
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The first detected layer in most OCT scans is the 
ILM that appears as a hyper-reflective layer at the 
vitreoretinal interface. Occasionally, the posterior 
hyaloid can be seen above the ILM as a hyper-
reflective layer. Within the retina, the RNFL, IPL and 
OPL are seen as hyper-reflective while the GCL and 
the nuclear layers are hypo-reflective. The retinal 
vessels may sometimes be seen on OCT images as 
circular hyper-reflective structures located in the 
inner retina, with a vertical shadow or reduced 
reflectivity extending into deeper layers (Drexler W, 
Sattmann H, 2003, Schuman JS, Puliafito CA, 2004; Spaide RF, 
Curcio CA, 2011).  
Outside the central fovea, SD-OCT instruments 
typically resolve four bands in the outer retina. The 
innermost band has been attributed to the ELM. 
This band is typically thinner and fainter than the 
others.  The second of the four bands has been 
commonly described to the boundary between the 
IS/OS of the photoreceptors and the third band is 
referred to as Verhoeff’s membrane. The fourth 
hyper-reflective outer retinal band is attributed to the 
RPE, with potential contribution from Bruch’s 
membrane and choriocapillaris, with abundant 
experimental and clinical evidence supporting this 
designation (Zawadzki RJ, Jones SM et al., 2005; Alam S, 
Zawadzki RJ et al., 2006; Srinivasan VJ, Ko TH et al., 2006; 
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Srinivasan VJ, Monson BK et al., 2008; Spaide RF, Curcio CA, 2011) 
(Fig. 8). 
 
Fig. 8: (A) Example of a normal eye image with the Spectralis OCT 
high resolution. (B) Four hyper-reflective bands in the outer retina; 
ELM, IS/OS, Verhoeff’s membrane and the RPE/Bruch’s membrane 
complex. (NFL: nerve fiber layer; GCL: ganglion cell layer; IPL: inner 
plexiform layer; OPL: outer plexiform layer; ONL: outer nuclear layer; 
ELM: external limiting membrane; IS/OS: photoreceptor inner/outer 
segment junction; RPE: retinal pigment epithelium (by Ryan S. 2013). 
 
1.12 OCT findings in Macular Diseases  
Hard exudates are hyper-reflective lesions that look 
like hyper-reflective shades of neurosensory retina 
that completely block the reflections of the 
underlying retina. Thin hemorrhages are hyper-
reflective, and if bleeding is thick, it can block the 
reflections of the underlying structures. Also 
epiretinal membrane (ERM), atrophy and all fibrotic 
lesions are hyper-reflective (Gupta V, 2004) (Fig. 9). 
The hypo-reflective lesions are serous fluid that 
produces an optically empty space without 
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backscatter and pseudocysts characterized as a 
round or oval areas of low reflectivity in the layers of 
the retina (Gupta V, 2004) (Fig. 10). 
 
Fig. 9: Spectralis OCT 5mm horizontal line scan passing through the 
foveal center. Note the pseudocyst (green arrow) as an oval area of 
low reflectivity. Also, note the presence of hyper-reflective band ERM 
(red arrow) and a macula atrophy (blue arrow). 
 
Fig. 10: Spectralis OCT 5mm horizontal line scan passing through the 
foveal center. Note the presence of hypo-reflective lesions; 
pseudocyst (red arrow) subretinal fluid (green arrow) and diffuse 
retinal thickness (blue arrow). 
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1.13 Pattern of OCT in Retinal Vascular Diseases 
1.13.1 OCT in Diabetic Macular Edema (DME) 
For the management of diabetic maculopathy, OCT 
is an important tool for assessing retinal pathology, 
including retinal thickness, DME, intraretinal 
exudates, vitreomacular interface abnormalities, 
subretinal fluid, and photoreceptor IS/OS junction 
abnormalities. OCT is also important in monitoring 
the response to treatment of DME by laser, 
intravitreal pharmacotherapies, and vitreoretinal 
surgery. 
DME can be associated with diffuse retinal 
thickening, cystoid macular edema (CME), serous 
retinal detachment or subretinal fluid, and 
vitreomacular interface abnormality (Otani T et al., 1999; 
Kim BY et al., 2006; Soliman W et al., 2008). 
Diffuse retinal thickening is usually defined as a 
sponge-like swelling of the retina with a generalized, 
heterogeneous, mild hypo-reflectivity compared with 
normal retina. CME is characterized by the 
presence of intraretinal cystoids areas of low 
reflectivity, which are typically separated by highly 
reflective septa (Fig. 11). Serous retinal detachment 
is defined on OCT as a focal elevation of 
neurosensory retina overlying a hypo-reflective, 
dome-shaped space (Fig. 12).  The posterior border 
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of the detached retina is usually highly reflective, 
which helps to differentiate subretinal from 
intraretinal fluid. Vitreomacular interface 
abnormalities include the presence of ERMs, VMT, 
or both (Otani T et al., 1999). 
 
Fig. 11: Spectralis OCT 5mm horizontal line scan passing through the 
foveal center in an eye with DME. Note the large pseudocyst (yellow  
arrow), the sponge-like swelling of the retina (red arrow) and cystoid 
macular  edema (green arrow) nasal to the fovea. 
 
 
Fig. 12: Spectralis OCT 5mm verticall line scan passing through the 
foveal center in patient with DME. Note the presence of intraretinal 
cystoids areas of low reflectivity (red arrow), which are typically 
separated by highly reflective septa and a focal elevation of 
neurosensory retina overlying a hypo-reflective, dome-shaped space 
corresponding a serous retinal detachment (green arrow). 
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In the last decade, many agents like triamcinolone 
and anti-VEGF have been studied to treat DME. 
Michaelides M et al. mentioned that the OCT played 
an important role in determining the retinal thickness 
and the treatment response (Elman MJ et al., 2011; 
Michaelides M et al., 2010). Kim NR et al. reported that the 
treatment responses of each OCT pattern of DME 
are different. Patients with diffuse retinal thickening 
may achieve a greater reduction in retinal thickness 
and a greater improvement in visual acuity 
compared with patients exhibiting CME, subretinal 
fluid, or vitreomacular interface abnormality (Kim NR et 
al., 2009; Soliman W et al., 2008). 
 
Fibrovascular proliferation in Proliferative Diabetic 
Retinopathy (PDR) can be visualized with OCT 
imaging as highly reflective preretinal bands anterior 
to the retinal surface. Diffuse retinal thickening, 
distortion, and irregularity of the retinal contour can 
also occur as a result of the contraction of these 
preretinal membranes. An associated traction retinal 
detachment may be observed as well (Fig. 13). 
OCT imaging is valuable in determining the extent 
of the tractional component as well as the presence 
of foveal involvement, assisting in the decision to 
intervene surgically (Haller JA et al., 2010). 
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Fig. 13: Spectralis OCT: 5mm vertical line scan through the macula in 
a patient with PDR. Note the highly reflective preretinal band anterior 
to the retinal surface (green arrow) and the diffuse retinal thickening 
(red arrow), distortion and the irregularity of the retinal contour. 
 
1.13.2 OCT in Branch Retinal Vein Occlusion 
(BRVO) 
BRVO is the second most common vascular 
disease of the retina after DR, it is usually caused by 
a thrombus at arteriovenous crossings where a 
thickened artery compresses the underlying venous 
wall (Duker JS, Brown GL, 1989).  
BRVO is usually seen in elderly patients, between 
60-70 years old; this pathology is associated with 
hypertension in 50 to 70% of the cases, 
cardiovascular disease, diabetes mellitus, and 
open-angle glaucoma (Duker JS, Brown GL, 1989; Spaide RF 
et al., 2003).   
OCT findings include CME (Fig.14), serous retinal 
detachment, ERMs, pseudoholes, lamellar holes 
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(Fig.15), and subhyaloid or preretinal hemorrhages 
in BRVO. A significant proportion of patients with 
occlusion of the retinal venous system have OCT 
evidence of CME and serous retinal detachment (Ota 
M et al., 2008; Shroff D et al., 2008; Ryan S et al., 2013).  
 
Fig. 14: Spectralis OCT 5mm horizontal line scan passing through the 
foveal center in patient with BRVO. Note the alteration in the foveal 
depression (red arrow) due to CME (green arrow) in an inferior-
temporal retinal vein occlusion.  
 
Fig. 15: BRVO associated with a lamellar macular hole, imaged by 
Spectralis OCT. Note the thin irregular foveal floor and split foveal 
edges (green arrow) accompanied with pseudocyst (red arrow). 
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1.13.3 OCT in Central Retinal Vein Occlusion 
(CRVO) 
CRVO is usually caused by a thrombus in the area 
of the lamina cribrosa. It is associated with 
hypertension in 60% of patients. Usually seen in 
elderly patients over 50 years old and there is a 
slight male predilection (Hayreh SS, Zimmerman MB, 1994). 
OCT plays a major role in studying macula in 
CRVO. In CRVO, the morphological findings visible 
in OCT include macular thickening, intraretinal cyst 
formation (Fig.16), lamellar macular holes, 
subretinal fluid accumulation, ERM and papilledema 
(Catier A et al., 2005; Lerche RC et al., 2001; Ozdemir H et al., 2005).  
The quantification of macular edema is 
demonstrated on OCT as a changes on the foveal 
depression, hypo-reflective areas of fluid 
accumulation and pseudocysts. Intraretinal 
hemorrhages appear as focal areas of bright and 
hyper-reflective backscattering which partially 
shadow the reflections from the retinal pigment 
epithelium and choriocapillaris (Ryan S et al., 2013).  
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Fig 16:  Spectralis OCT image shows a macular thickening, 
intraretinal cyst formation (red arrow) with a hypo-reflective subretinal 
fluid accumulation (green arrow) in CRVO. 
 
1.13.4 Principles of the treatment of Retinal 
Vascular Diseases 
Focal laser photocoagulation reduces the risk of 
moderate visual acuity loss by 50% of the patients 
with DME and reserved for the noncenter involved 
edema. Other treatments modalities for DME 
include intravitreal injection of anti-VEGF drugs and 
corticosteroids. In case of associated vitreomacular 
traction is a macular surgery recommended.  
The response to various treatments modalities for 
macular edema is variable. Some patients show 
excellent visual improvement whereas others show 
only minimal response. Therefore OCT plays a 
pivotal role in quantitatively monitoring changes in 
retinal thickness after treatment such as intravitreal 
corticosteroid and anti-VEGF injection or 
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photocoagulation (Greenberg PB, Martidis A, 2002; Martinez-
Jardon CS, Meza-de Regil A, 2005). 
 
1.14 OCT in Vitreoretinal Interface Disorders 
Abnormalities of the vitreoretinal interface are 
involved in the pathogenesis of several macular 
conditions. In idiopathic epiretinal membranes 
(ERMs), a layer of fibrotic tissue develops on the 
surface of the retina, usually after a posterior 
vitreous detachment. Contraction of this membrane 
can result in retinal distortion, leading to vision loss. 
In other conditions, such as vitreomacular traction 
syndrome (VMTS) or idiopathic macular hole (IMH), 
there are abnormal attachments between the 
vitreous and the retina. The resulting traction 
exerted on the retina causes anatomical alteration 
and subsequent visual loss. 
1.14.1 Vitreomacular traction syndrome (VMTS) 
VMTS results from persistent vitreoretinal adhesions 
after the development of partial posterior vitreous 
detachment (PVD). In normal eyes, as the vitreous 
liquefies due to age, it detaches from the macula. 
This natural progression has been demonstrated 
using OCT (Uchino E et al., 2001). In some eyes, due to 
the strong adhesion between the vitreous and 
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macula, the vitreous detaches peripherally, and 
continues to pull on areas of the macula. The 
vitreoretinal adhesions transmit tractional forces to 
the retina from the vitreous body, having the 
potential to cause tensile deformation (Fig.17), 
foveal cavitations, CME, limited macular 
detachment, or a macular hole (MH) (Schmiddy WE et 
al., 1989;  Jhonson MW, 2005).  
In recent years OCT has been most beneficial in 
diagnosing VMTS and subsequently directing 
treatment of this condition. 
Sulkes DJ et al. mentioned that in some people 
spontaneous resolution can occur with separation of 
the vitreous from the macula, leading to subsequent 
resolution of the intraretinal and subretinal fluid and 
restoration of normal vision (Sulkes DJ et al. 2000). 
However, in most eyes, VMTS may persist and 
intravitreal Ocriplasmin or vitrectomy may be an 
effective treatment option for patients with 
symptomatic VMTS. Consequently, OCT is useful in 
monitoring subtle changes in vitreoretinal adhesions 
and retinal architecture and assisting the treatment 
decision-making process (Yamada N, 2005; Witkin AJ et al. 
2010). 
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Fig. 17: Spectralis OCT shows persistent vitreous adhesion at the 
foveola (green arrows) causing tractional foveolar thickening with 
cyst-like spaces (red arrow). This type of vitreofoveolar traction is a 
subtle variant of the vitreomacular traction syndrome. 
1.14.2 Epiretinal membrane (ERM) 
ERM occurs in approximately 6% of patients over 
the age of 60, with incidence increasing with age 
(Mccarty DJ et al., 2005). ERMs are idiopathic or 
secondary to an initiating event. Most idiopathic 
ERMs are thought to result from fibroglial 
proliferation on the inner surface of the retina 
secondary to a break in ILM occurring during PVD 
(Smiddy WE, Maguire AM et al, 1989). Secondary ERMs 
result from an already existing ocular pathology 
such as CRVO, BRVO, DR, uveitis, and retinal 
breaks with or without detachment (Appiah AP, Hirose T, 
1989). 
Glial cells, RPE cells, and myofibroblasts are shown 
to be mostly involved in ERM formation. (Smiddy WE, 
Maguire AM et al, 1989; Vinores SA et al.,1990).  ERM may 
lead to loss of normal retinal anatomy, with the 
patient experiencing metamorphopsia, micropsia, 
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monocular diplopia, and decreased visual acuity. 
These symptoms vary in severity depending on the 
location, density, and contraction of the membrane. 
Sometimes, ERMs can evolve into macular 
pseudoholes and ERMs are often seen in 
conjunction with idiopathic full-thickness macular 
holes (Schmiddy WE, Michels RG et al., 1990).  
OCT provides qualitative and quantitative 
information about the retinal anatomy, which can 
identify factors contributing to vision loss in patients 
with ERM.  
On OCT, ERMs are seen as a highly reflective layer 
on the inner retinal surface (Fig. 18). In most eyes, 
the membrane is globally adherent to the retina 
(Fig. 19) but, in some cases, it can be separated 
from the inner aspect of the retina, which enhances 
its visibility by OCT. In this situation, it is usually 
distinguishable from a detached posterior hyaloid. 
Secondary effects of the membrane include loss of 
the normal foveal contour, increased retinal 
thickness, and the presence of cystoids changes, 
and these features may be observed in more 
advanced membranes.  
OCT is also useful for monitoring changes in cases 
that are being observed and for documenting the 
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response to treatment in patients undergoing pars 
plana vitrectomy with membrane peeling. 
 
Fig. 18:  Spectralis OCT shows the presence of hyper-reflective band 
(green arrow) at the vitreoretinal interface with traction on the 
underlying retina resulting in distortion of neurosensory retinal layers 
(red arrow). 
 
Fig. 19: Spectralis OCT shows a hyper-reflective band corresponding 
an epiretinal membrane globally adherent to the retina and a loss of 
the foveal depression. 
 
1.14.3 OCT in Macular Holes 
Idiopathic macular holes (IMHs) typically occur in 
the sixth to seventh decade of life with a 2: 1 female 
preponderance. Symptoms include decreased 
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visual acuity, metamorphopsia, and central 
scotoma. Bilateral involvement occurs in 15–20% of 
patients.  
A full-thickness defect in the neural retina as seen 
with OCT can differentiate a true macular hole from 
a pseudohole, lamellar macula hole, or a macular 
cyst. Lamellar macula holes show an increased 
foveal pit contour with a thin outer neurosensory 
retina (Fig. 20). Macular pseudoholes are seen in 
the presence of a dense ERM with a central defect 
that overlies the foveal center, giving the 
ophthalmoscopic appearance of a true macular hole 
(Schumann JS, Puliafito CA, 2004) (Fig. 21).  
 
Fig. 20: Main Spectralis OCT features shows a lamellar hole. Note 
the horizontal splitting of the foveal edges, irregularity of the foveal 
base and thinning of the outer neurosensory retina. 
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Fig. 21: Spectralis OCT features shows a pseudohole. Note the 
presence of a dense ERM (green arrows) with a steep configuration 
of the foveal edge (red arrow). 
 
Gass described the stages of full-thickness MH 
formation based on biomicroscopic findings (Gass JD, 
1995).  
Stages 1 holes may be distinguished by a reduced 
or absent foveal pit and the presence of an optically 
clear space beneath the fovea, suggesting a 
foveolar detachment. Evidence of traction by the 
posterior hyaloid on the fovea may be present. 
Stage 2 holes show a partial break in a surface of 
the retina with a small full-thickness loss of retinal 
tissue, <400 µm in size (Fig. 22). 
Stage 3 holes have a full-thickness retinal 
dehiscence >400 µm in size with a complete break 
in the outer retinal tissue, and variable amounts of 
surrounding macular edema that increase retinal 
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thickness and decrease reflectivity in the outer 
retinal layers.  
Stage 4 holes can be characterized by the complete 
loss of tissue >400 µm in size, and a complete 
detachment of the posterior vitreous (Fig. 23). 
Stage 1 and 2 macular holes are very difficult to 
differentiate ophthalmoscopically and high 
resolution OCT images can help to classify them. 
Stage 2 often progresses to stage 3 with some 
visual loss; therefore, appropriate staging with OCT 
can help to determine when surgery is necessary 
(Gass JD, 1990). 
Pars plana vitrectomy with and without ILM peeling 
has become the standard treatment for macular 
hole with anatomical success rates of 85–100% 
(Kelly NE, Wendy RT,  1991; Brooks HL JR, 2000). OCT can be 
used to confirm complete macular hole closure and 
restoration of the normal foveal contour. 
 
Fig. 22: Spectralis OCT shows a stage 2 macular hole. A small full-
thickness loss of retinal tissue, <400 µm in size.  
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Fig. 23: Spectralis OCT shows a stage 4 macular hole. A full-
thickness retinal defect >400µm and a complete detachment of the 
posterior vitreous (green arrow).  
 
1.15 OCT in Age-related macular degeneration 
(ARMD) 
ARMD is a progressive degenerative disease of the 
retinal pigment epithelium, Bruch’s membrane, and 
choriocapillaris. It is classified in two forms: non-
neovascular (dry) and neovascular (wet or 
exudative). The non-neovascular form accounts for 
80–90% of cases while the neovascular form 
accounts for 10–20% of cases, but was responsible 
for the majority of severe vision loss (80–90%) prior 
to the widespread use of vascular endothelial 
growth factor (VEGF) inhibitors. Occasionally, the 
dry form can develop into the wet (Friedman DS et al., 
2004; Klein R et al., 2004). 
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ARMD is the most common cause of central vision 
defects in the elderly in the Western countries over 
50 years population (Klein et al. 1998; Age Related Eye 
Disease Study Research Group 2000), It is estimated that 
approximately 30% of adults older than 75 years 
have some sign of ARMD and that approximately 
10% of these patients have advanced stages of the 
disease. 
Patients with advanced ARMD in one eye, or even 
moderate vision loss due to non-advanced ARMD in 
one eye, have about a 50% chance of developing 
advanced ARMD in the fellow eye within 5 years.  
Risk factors include increasing age (>75 years of 
age), positive family history, cigarette smoking, 
hyperopia, hypertension, hypercholesterolemia, 
female gender, and cardiovascular disease; 
nutritional factors and light toxicity also play a role in 
pathogenesis. There may also be a genetic 
component to ARMD (Hirvela H et al., 1996; Vingerling JR et 
al. 1996). 
 
1.15.1 Non-neovascular ARMD  
Non-neovascular (dry) ARMD is characterized by 
abnormalities of the RPE, Bruch’s membrane, and 
choriocapillaris. These abnormalities may be 
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asymptomatic or accompanied by compromised 
vision, and are considered to be the precursors of 
geographic atrophy (GA) and choroidal 
neovascularization (CNV) (Hirvela H et al., 1996; Vingerling 
JR et al. 1996). 
Drusen appear clinically as focal white-yellow 
excrescences deep to the retina. They vary in 
number, size, shape, and distribution. The high-
definition B-scans obtained with SD-OCT are useful 
to assess the ultrastructure of drusen and to 
evaluate for evidence of disruption of adjacent 
retinal layers (Fig. 24). Soft drusen are observed as 
focal elevations in the external, highly reflective 
band (RPE/choriocapillaris complex) consistent with 
the accumulation of amorphous material within or 
beneath Bruch’s membrane (Sikorski BL et al., 2010; 
Spaide R, Curcio CA 2010) (Fig. 25). 
In larger drusen or drusenoid retinal pigment 
epithelial detachments (PEDs), the RPE has a 
greater elevation with a dome-shaped configuration 
(Roquet W et al., 2004) (Fig. 26). 
Larger drusen may often become confluent and can 
sometimes be accompanied by fluid accumulation 
under the retina in the absence of CNV (Sikorski BL et 
al., 2010). Recognition of this feature may avoid 
unnecessary treatment with anti-VEGF drugs. 
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Fig. 24: Spectralis OCT shows the presence of drusen (red arrow) as 
a focal elevation between the retinal pigment epithelium and 
membrane Bruch’s. 
  
Fig. 25: Spectralis OCT shows the presence of large drusen (red 
arrow) and atrophy of the outer segments of the fovea (green arrow) 
in ARMD. 
 
Fig. 26:  Spectralis OCT shows a drusenoid RPE detachment (red 
arrow).  
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atrophy (GA) is seen clinically as one or more areas 
of hypopigmentation or depigmentation due to the 
absence of the underlying RPE. The deeper 
choroidal vessels are more readily visualized 
through the atrophic areas, and are accompanied by 
varying degrees of photoreceptor and 
choriocapillaris loss (Fig. 27). Associated retinal 
atrophy is seen as thinning or loss of the outer 
nuclear layer and the absence of ELM and IS/OS 
junctions (Fleckenstein M et al. 2008). The loss of 
photoreceptors often extends beyond the margins of 
GA, with the ELM and IS/OS junctions disappearing 
while bridging across the GA margin. Evaluation of 
these junctional zones may provide information 
about the pathogenesis of GA, and the role of RPE, 
photoreceptor, and choriocapillaris loss in the 
initiation and propagation of this condition (Bearelly S et 
al. 2009). SD-OCT has been shown to be useful in 
detecting some of these morphologic 
alterations (Fig. 27). 
Hyperpigmented RPE areas (hypertrophy or 
hyperplasia) in OCT show a high reflectivity from the 
RPE with shadowing of the reflections from the 
choroid. 
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Fig. 27: Spectralis OCT shows a geographic atrophy (red arrow) in a 
patient with ARMD. Note the photoreceptor loss. 
 
1.15.2 Neovascular ARMD 
The neovascular (wet) form of ARMD is 
characterized by the overproduction of VEGF and 
the growth of abnormal vessels in the macular 
region. These vessels arise from the choroidal 
circulation and penetrate Bruch’s membrane to form 
a fibrovascular tissue beneath or above the RPE, or 
these vessels may arise primarily from the retinal 
circulation. The presence of VEGF and abnormal 
vessels leads to structural changes in the retina and 
choroid with the accumulation of fluid within the 
retina, in the subretinal space, or under the RPE. 
Furthermore, this neovascular invasion may lead to 
significant disorganization and remodeling of the 
retina, resulting in the loss of the RPE and 
photoreceptors with the formation of a disciform 
scar (Green WR, 1999). 
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OCT is very useful in detecting intraretinal, 
subretinal, or sub-RPE fluid. In patients with active 
neovascular ARMD, OCT imaging can be used to 
establish baseline retinal thickness, and determine 
the extent of neovascularization, fluid involvement, 
and other lesion components (blood, fluid, pigment, 
and fibrosis). 
The growth of neovascularization is often 
accompanied by VEGF-dependent leakage from 
both the mature vessels and the growing immature 
vessels (Schuman JS, Puliafito CA, 2004). Choroidal 
neovascularization is characterized by increased 
optical reflectivity of the RPE or disruption of the 
highly reflective band layer RPE/choriocapillaris 
(Fig. 28). Intraretinal edema appears as an area of 
low intraretinal reflectivity, which corresponds to 
intraretinal fluid accumulation and is consistent with 
an increased retinal thickness. Lipid exudation can 
also be present in patients with profuse intraretinal 
edema and appear as small hyper-reflective dots in 
the outer retina. The fluid may also accumulate in 
the space between the RPE and the neurosensory 
retina (Fig. 28).  
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Fig. 28: Spectralis OCT shows the presence of choroidal 
neovascularization (green arrow), intraretinal fluid accumulation (red 
arrow) and cystoid macular edema (blue arrow) in ARMD.  
A pigment epithelium detachment (PED) 
demonstrates an elevation of the reflective band 
corresponding to the RPE/choriocapillaris complex 
and shadowing of the reflections returning from the 
deeper choroid. In contrast, neurosensory retinal 
detachment appears as elevations of the sensory 
retina above an optically clear space (Fig. 29). 
 
Fig. 29: Spectralis OCT shows the presence of PED (blue arrow), and 
neurosensory retinal detachment that appears as elevations of the 
sensory retina above an optically clear space (subretinal fluid 
accumulation) (red arrow) in ARMD. 
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Disciform scarring and subretinal fibrosis are the 
end stage of CNV. The vascular components of 
CNV typically regress as the lesion becomes less 
active, and the fibrous components typically 
increase, resulting in disciform scar formation. 
Clinically the scar appears as smooth, elevated 
white or gray tissue in the subretinal space and on 
OCT imaging the scar corresponds to a highly 
reflective outer retinal or subretinal lesion 
(Schuman JS, Pulliafito CA, 2004) (Fig. 30). 
 
Fig. 30: Spectralis OCT shows the presence of disciform scarring (red 
arrow) as a highly reflective subretinal lesion between the retinal 
pigment epithelium and Bruch’s membrane. 
 
1.16.3 Treatment of ARMD 
There are several types of treatments for ARMD. 
Argon laser photocoagulation is a therapy for cases 
where the CNV is extrafoveal. Photodynamic 
therapy (PDT) is a cold laser irradiation to 
specifically destroy the neo-vessels, particularly 
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subfoveal CNV. The Anti-VEGF agents are drugs 
that bind to and block the activity of VEGF (Bandello F, 
Battaglia Parodi M, Siemerink MJ et al, 2010). Currently, the 
intravitreal anti-VEGF application is the gold 
standard for the treatment of neovascular ARMD. 
The macular surgery is deserved for some 
complicated cases, such as large submacular 
hemorrhages in ARMD. 
 
   1.17 Anti-VEGF treatments  
Even though the reasons and the clinic of these 
diseases are different, most of the vascular 
diseases of the retina and choroid are associated 
with exudative changes in the macula except 
epiretinal membrane. These changes are leading to 
damage of the photoreceptors and causing vision 
loss. New hopes in treating all of these diseases are 
the anti-VEGF therapy. 
VEGF is a protein that occurs naturally within the 
body. Bodily tissues are thought to release this 
protein to signal the need for additional oxygen. 
Nearby blood vessels can sense the presence of 
this protein and in response, sprout and grow new 
blood vessels that extend into the VEGF releasing 
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tissue. This brings new pathways of blood supply 
into the oxygen needed tissue.  
Many times the activity of VEGF is helpful, but for 
example after a CRVO,  VEGF is thought to 
contribute to macular edema by increasing the 
permeability of the capillary walls, allowing fluids 
and proteins to make their way into the macular 
tissue. VEGF is also thought to be the culprit that 
stimulates the formation of the abnormal, fragile 
vessels of neovascularization.  
Anti-VEGF agents are drugs that bind to and block 
the activity of VEGF (Bandello F, Battaglia Parodi M, 
Siemerink MJ et al., 2010). 
 
1.17.1 Ranibizumab (Lucentis) 
This is a recombinant humanized monoclonal 
antibody antigen-binding fragment (Fab)  that 
neutralizes all known active forms of vascular 
endothelial growth factor A (VEGF-A), a protein that 
is believed to play a critical role in the formation of 
new blood vessels. Ranibizumab is an Anti-VEGF 
developed specifically for use in the eye. The usual 
dose of intravitreal injection is 0.5 mg in 0.05 ml.  
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Three main treatment strategies are currently 
adopted .The first strategy is a regular monthly 
injection that  is the regimen adopted in initial major 
trials. Overall, around 95% of patients maintain 
vision regardless of lesion type, and 35–40% 
significantly improved, most markedly during the 
first 3 months. The second strategy is the three 
initial monthly injections followed by monthly review 
with re-injection when deterioration occurs as 
assessed by VA and OCT and the third strategy is 
the ‘treat and extend’ that administer three initial 
injections at monthly intervals and then gradually 
increasing the period between injections until 
deterioration is evident. If possible a tailored interval 
is determined for each patient. (Bandello F, Battaglia 
Parodi M, Schmidt-Erfurth U et al, 2010).  
1.17.2 Bevacizumab (Avastin)  
This is a recombinant humanized monoclonal 
antibody that produces angiogenesis inhibition by 
inhibiting VEGF-A. In contrast to ranibizumab (48 
kDa), bevacizumab is a complete antibody (149 
kDa). The indication is macula edema and 
proliferative (neovascular) eye diseases, particularly 
for CNV in ARMD (Bandello F, Battaglia Parodi M, Schmidt-
Erfurth U et al, 2010). The usual dose of intravitreal 
injection is 1.25 mg/0.05 mL or 2.5 mg/0.1 ml. 
(Arevalo JF, et al. 2008). 
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According to the Comparison of Age-related 
Macular Degeneration Treatment Trials (CATT) 
study, there is no clinical significant difference or 
inferiority between ranibizumab and bevacizumab in 
treating patients with ARMD. (Martin DF et al., 2012). 
1.17.3 Pegaptanib (Macugen)  
Pegaptanib sodium was the first anti-VEGF agent 
approved by regulatory authorities for ocular 
treatment. Although offering visual outcomes 
superior to photocoagulation, the results are similar 
to outcomes with PDT, and use of pegaptanib is 
considerably less widespread than other anti-VEGF 
agents (Bandello F, Battaglia Parodi M, Schmidt-Erfurth U et al, 
2010). 
1.17.4 Aflibercept (Eylea) 
Aflibercept is a novel VEGF inhibitor, with a high 
affinity for VEGF. It is a protein constructed by 
fusion of the second binding domain of the receptor 
VEGFR1 and the third binding domain of the 
receptor VEGFR2 to the crystalline portion of IgG1. 
This has resulted in aflibercept’s having a 
significantly higher affinity in vitro to VEGF 
compared with both bevacizumab and ranibizumab 
(Holash J et al. 2002; Stewart MW, Rosenfeld PJ, 2008; Stewart MW, 
2012; Bakall B et al. 2013).
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2. Material and Methods 
 
2.1 General objective: 
Determine the agreement between the general 
ophthalmologist and retina specialist in the 
diagnosis and classification of macular diseases by 
high- definition spectral-domain optical coherence 
tomography (Spectralis OCT). 
 
2.2 Hypothesis 
Hypothesis (H1): There is statistically significant 
difference in agreement between the general 
ophthalmologist and the retina specialist to 
recognize findings by Spectralis OCT. 
Null hypothesis (H0): There is no statistically 
significant difference in agreement between the 
general ophthalmologist and the retina specialist to 
recognize findings by Spectralis OCT. 
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2.3 Definitions 
Degree of agreement: Is the concordance among 
raters. It gives a score of how much homogeneity, 
there is in the ratings given by judges. 
Not in agreement: Is the discordance between 
raters. 
Nongradable: No decision because of the poor 
image quality. 
Limits of agreement: Refers to calculate the 
differences between each pair of observations of the 
two raters. The average of these differences is 
called bias and the reference range (mean + / - 1.96 
x standard deviation) is termed limits of agreement. 
 
2.4 Study population 
After taken the approval by the Ethics committee 
das Institut für Klinische Epidemiologie und 
angewandte Biometrie der Eberhard Karls 
Universität zu Tübingen. We performed a 
retrospective chart review of patients who visited 
der Eberhard Karls, Universitäts-Augenklinik, 
Tübingen between August 2009 and September 
2012. Clinical records of consecutive patients, 
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diagnosed with neovascular ARMD, BRVO, CRVO, 
BRVO, DME, and ERM that Spectralis SD-OCT 
examination with linear scan protocol were included 
in this study. In total, data of 500 patients were 
evaluated. 
All patients underwent complete ophthalmic 
examination and Spectralis OCT. Fluorescein 
angiography and indocyanine green angiography 
were performed in some of the patients if needed. 
Using the digital chart system, list of the patients 
with predefined diseases were found. 
 
2.5 Inclusion criteria 
1. Patients with neovascular ARMD, BRVO, CRVO, 
DME and ERM. 
2. Patients older than 18 years old. 
3. Fundus photography and fluorescein angiography 
(except for eyes with ERM) at baseline. 
4. Available Spectralis OCT examination of the 
macula. 
5. Morphological abnormalities at the macula 
detected on the Spectralis OCT examination. 
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2.6 Exclusion criteria 
1. Eyes having more than one disease affecting the 
macula (for example, neovascular ARMD and 
BRVO on the same eye). 
2. The second eye of the included patients. 
3. Eyes with poor quality of fundus photographs or 
fluorescein angiography. 
 
2.7 Selection of the study population 
After considering the inclusion and exclusion 
criteria, for each of the predetermined five diseases, 
100 eyes of each disease were included into the 
analysis. All of the 500 consecutive eyes were 
selected by a senior ophthalmologist (FG) of the 
Department of Retina after checking the patient’s 
charts and Spectralis OCT scans. 
Eyes were selected if morphological abnormalities 
at the macula were seen on the Spectralis OCT 
examination. 
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2.8 Design   
This study is transactional, correlational, and 
retrospective; because we analyze significant 
morphological findings (variables) that are 
presented in each disease into a single image at a 
time, also the relationship that exists between intra 
and interobserver. 
 
2.9 Design description. 
In September 2012, images (vertical and horizontal 
linear scans do Spectralis OCT) of the patient's first 
visit were selected by the general ophthalmologist 
(examiner 1). By that time the central retinal 
thickness (CRT) was measured in both images, 
determining the average value of the 500 eyes of 
500 patients with the diagnosis categories noted 
above. After that the variables of the 5 groups were 
assessed, in addition to assessing the quality of the 
image by the OCT. 
Between September 2012 and December 2012, the 
general ophthalmologist learned to use the 
Spectralis OCT in high resolution as well as, 
interpret and diagnose macular disorders during the 
clinical routine. 
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In December 2012, the second measurement of the 
CRT was repeated by the same general 
ophthalmologist; the same OCT image-scans were 
used as before.  
In March 2013, the retina specialist (examiner 2), 
with an experience of performing and analyzing of 
the Spectralis OCT evaluated the CRT as well as 
the variables of the included eyes. 
 
2.10. Sample size 
For the analysis, we included into the study 500 
images of 500 eyes (500 patients) with predefined 
macular diseases. 
These were:  
1- 100 eyes (100 patients) with age-related 
macular degeneration (ARMD). 
2- 100 eyes (100 patients) with branch retinal 
vein occlusion (BRVO). 
3- 100 eyes (100 patients) with central retinal 
vein occlusion (CRVO). 
4- 100 eyes (100 patients) with diabetic macular 
edema (DME). 
5- 100 eyes (100 patients) with epiretinal 
membrane (ERM). 
 
  
 
56 
2.10.1 Analyses of the OCT scans 
In all patients, the macula was scanned in the 
horizontal and vertical meridians using the standard 
lineal protocol of Spectralis OCT. The CRT was 
calculated for each image using a 5mm length 
centered through the fovea, twice by general 
ophthalmologist (HT), in September 2012 and 
December 2012 and thereafter by the retina 
specialist (ML) in March 2013. 
Data was obtained from the right eyes if both eyes 
fulfilled the inclusion criteria. 
 
2.11 Evaluation method 
 
2.11.1 Ophthalmologic examination 
All patients had a general ophthalmological 
examination including best corrected visual acuity, 
biomicroscopy of the anterior segment, 
measurement of the intraocular pressure and 
fundoscopy in mydriasis. All eyes had color fundus 
photography and Spectralis OCT. Fluorescein 
angiography and Indocyanine green angiography 
was performed if needed. 
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2.12 Examination protocol of the OCT 
 
2.12.1 Preparation of the patient 
After the eye examination, OCT was performed on 
patients with suspected macular alteration. 
1- Patient data was given. 
2- Pupillary dilation. 
3- Positioning of the head of the patient 
(Supported of the front and chin). 
4- IR+OCT of Spectralis. 
 
Spectralis OCT examinations were performed by an 
ophthalmologist or technician. 
 
2.12.2 Preparation of the OCT 
OCT scans included in this Study were generated 
using Heidelberg Engineering, HTR-OCT Spectralis, 
and version 1.8.6.0. Heidelberg, Germany (Fig.31) 
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Fig. 31: Spectralis OCT (Heidelberg Engineering, Heidelberg,        
Germany). 
 
2.12.3 Settings of Spectralis OCT 
Eye:  OD/OS  
Angle: 0-90 grades 
Focus:  -10 to10 Diopters 
Sensibility:  >59 
Power: IR 100% 
Rate:  4.7 sec.  
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Resolution: High resolution 
Application structures: Retina  
Scan: Horizontal or vertical  
ART: 100 Frames A-Scans: 1024 to 1536 
 
Fig. 32: Spectralis OCT horizontal line scan shows the layers of the 
retina and measurement of CRT. ILM: internal limiting membrane; 
NFL: nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform 
layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer 
nuclear layer; ELM: external limiting membrane; IS/OS: photoreceptor 
inner/outer segment junction; RPE: retinal pigment epithelium. 
 
Fig. 33: Spectralis OCT vertical line scan shows CRT measurement 
from ILM to RPE/Bruch membrane complex. 
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The CRT was manually measured in all scans using 
the manual caliper tool built into the OCT software 
(Fig. 32, 33) twice by HT, in September 2012 and 
December 2012 and again by ML in March 2013. 
Both examiners were masked to any clinical, 
angiographic or functional status of the eyes when 
grading the scans.  
CRT was defined as the interface between the dark 
vitreous and the bright reflection of the internal 
limiting membrane (ILM) and the outer retinal 
surface of the bright retinal pigment 
epithelium/Bruch’s membrane complex at the fovea. 
Measurements were taken in the central 1mm of the 
OCT scans (Ian C, Han MD, Jaffe GJ, 2008) (Fig. 32, 33). 
In addition, all OCT scans were graded for the 
presence or absence of the following morphological 
findings: foveal depression, epiretinal membrane, 
vitreofoveolar traction, pseudocyst, splitting, 
verticalisation of the foveal edge, macular hole, 
pseudomacular hole, lamellar macular hole, 
neurosensory detachment of the retina, retinal 
pigment epithelium detachment, external limiting 
membrane, photoreceptors inner and outer 
segments. 
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2.13 Artifacts and Gradability of the images 
Each horizontal and vertical line scans were 
reviewed in terms of the gradability. Scans with 
significant image artifacts resulting in reliable 
thickness measurements of the retina were 
excluded. Reasons for scan exclusion included 
weak saturated scans where the boundaries of the 
retina or intraretinal morphology could not be 
identified adequately and off-center scans which 
were not centered within the foveal pit. 
For patients with multiple acceptable scans per eye 
in the same clinic visit, one scan per eye was 
chosen at random to be included in the study. 
 
2.14 Color fundus photography, Fluorescein 
angiography and Indocyanine green 
angiography 
All patients had color fundus photography of both 
eyes. Some patients underwent fluorescein and 
indocyanine green angiography at the first 
presentation to diagnose the macular pathology. 
These examinations were performed by skilled 
photographers at the imaging department. 
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2.15 Data analysis 
A coding scheme was conducted to evaluate the 
morphological findings (variables), as well as for the 
database. 
Abbreviation Text Type of 
scale 
Ranges of 
values 
Unit Role 
ID Number of 
patient 
 
Numeric 1-500 - Identification 
 
Examination 
 
Examination 
 
Numeric 
1.Septembe
r H.T 
2.December 
H.T 
3.March M.L 
  
Age Age of 
patient 
 
Statistic 30-100 Years Age 
Gender Gender Numeric M for Men 
W for 
Women 
- Gender 
Diagnosis Diagnosis of 
the eye 
Numeric 1. BRVO 
2. CRVO 
3. DME 
4. ARMD 
5. ERM  
- Diagnose 
Study eye Study eye Numeric L for Left 
R for right 
- Eye 
 
Exam Date 
 
Exam Date 
 
Statistic 
 
15.03.2008 
– 
16.03.2013 
 
Date 
 
CRT_FD_H Central 
retinal 
thickness of 
the fovea 
(horizontal 
scan of the 
study eye) 
 
Statistic 
 
0 – 1300 
 
Μm 
 
Microns 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
-  
Quality 
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2-No 
assessable 
 
CRT_FD_V Central 
retinal 
thickness of 
the fovea  
(vertical scan 
of the study 
eye) 
 
Statistic 
 
0 – 1300 
 
Μm 
 
Microns 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
-  
Quality 
CRT_FD_D Central 
retinal 
thickness of 
the fovea 
(Average) 
 
Statistic 
 
0 – 1300 
 
Μm 
 
Microns 
Fo_De Foveal 
Depression 
(of the study 
eye) 
Numeric 0-Normal 
1-Abnormal 
2- No 
assessable  
-NL 
-ANL 
-N/A 
 
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
 
ERM 
Epiretinal 
Membrane 
(of the study 
eye) 
 
Numeric 
 
0-No 
1-Yes 
2- No 
assessable 
 
 
- 
- 
N/A 
 
 
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
 
VFT 
Vitreofoveal 
traction (of 
the study 
eye) 
 
Numeric 
0-No 
1-Yes 
2- No 
assessable 
- 
- 
N/A 
 
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
Pseudocyst Pseudocyst Numeric 0-No -  
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(of the study 
eye) 
1-Yes 
2- No 
assessable 
- 
N/A 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
Splitting Splitting (of 
the study 
eye) 
Numeric 0-No 
1-Yes 
2- No 
assessable 
- 
- 
N/A 
 
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
 
Verticalisatio
n 
Walls of the 
foveal 
verticalisatio
n (of the 
study eye) 
 
Numeric 
0-No 
1-Yes 
2- No 
assessable 
- 
- 
N/A 
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
MH Macular Hole 
(of the study 
eye) 
Numeric 0-No 
1-Yes 
2- No 
assessable 
- 
- 
N/A 
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
PSM Pseudomacul
ar Hole  (of 
the study 
eye) 
Numeric 0-No 
1-Yes 
2- No 
assessable 
- 
- 
N/A 
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
LMH Lamellar 
Macular Hole 
(of the study 
eye) 
Numeric 0-No 
1-Yes 
2- No 
assessable 
- 
- 
N/A 
 
Quali_OCT Quality of Numeric 0-Good -  
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the OCT 1-Bad 
2- No 
assessable 
- 
N/A 
Quality 
 
NSD 
Neurosensor
y 
detachment 
(of the study 
eye) 
 
Numeric 
0-No 
1-Yes 
2- No 
assessable 
- 
- 
N/A 
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
 
 
PED 
 
Pigment 
epithelial 
detachment 
(of the study 
eye) 
 
 
Numeric 
 
0-No 
1-Yes 
2- No 
assessable 
 
- 
- 
N/A 
 
 
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
 
LMO 
 
Limiting 
membrane 
outer(of the 
study eye) 
 
Numeric 
 
0-Normal 
1-Abnormal 
2- No 
assessable 
 
-NL 
-ANL 
-N/A  
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
IS/OS Inner and 
outer 
segment 
junction 
Numeric 0-Normal 
1-Abnormal 
2- No 
assessable 
-NL 
-ANL 
-N/A 
 
Quali_OCT Quality of 
the OCT 
Numeric 0-Good 
1-Bad 
2- No 
assessable 
- 
- 
N/A 
 
Quality 
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2.16 Variables 
Of the 5 groups of diseases 13 morphological 
findings (variables) were obtained and analyzed.  
Definitions of the morphological findings (variables): 
1. Foveal depression: It is an excavation 
diameter of 1.5mm which corresponds to a 
slightly concave curvature on OCT image. An 
irregularity, a concavity or a convexity in an 
exaggerated foveal area could be suggestive 
to pathology. 
 
2. Epiretinal membrane: It is visible as a highly 
reflective layer on the inner retinal surface on 
OCT. 
 
3. Vitreofoveolar traction: It is characterized by 
the adhesion between the posterior vitreous 
and fovea. 
 
4. Pseudocyst:  It is characterized as a round or 
oval areas of low reflectivity in the layers of 
the retina. 
 
5. Splitting: The edges of the fovea are split by 
a cleft between the inner and outer retina. 
 
6. Verticalisation: The edges of the fovea have 
a vertical appearance. 
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7. Macular hole: It is characterized by an 
absence of foveal tissue. 
 
8. Pseudomacular hole: It is characterized by a 
steepened foveal pit combined with thickened 
foveal edges, verticalisation of the foveal 
slope and a small foveal pit diameter. 
 
9. Lamellar macular hole: It is characterized by 
a thin irregular foveal floor, split foveal edges 
and a near normal perifoveal retinal 
thickness. 
 
10.  Neurosensory detachment of the retina: It is 
a separation that occurs between RPE and 
the photoreceptors. 
 
11.  Pigment epithelium detachment: It is a 
separation that occurs between RPE    and 
Bruch’s membrane. 
 
12.  External limiting membrane: It is the 
junctions between photoreceptor cells and 
Müller cells. 
 
13.  Photoreceptors inner and outer segments: 
Are the layers of rods and cones 
(photoreceptors cells). 
(Haouchine B, Massin P, Tadayoni R, et al. 2004; 
Chang LK, Fine HF, Spaide RF, et al., 2008) 
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2.17 Statistical analysis 
For the statistical analysis, we consulted das Institut 
für Klinische Epidemiologie und angewandte 
Biometrie der Eberhard Karls Universität zu 
Tübingen.  
Statistical analysis was performed using JMP 
software version 10.0 (SAS Institute,Inc., Cary, NC) 
and  Microsoft Office Excel 2010 ® (Microsoft Corp., 
Seattle, WA).  
Tables and graphs from JMP 10 program were used 
to determine demographic data.  
For the statistical analysis of central retinal 
thickness (CRT) we used the individual differences 
analysis (Bland-Altman method) so it measured the 
concordance between 2 systems of measurement 
and it represented graphically the differences 
between 2 measurements front the mean.  
Paired t tests were used to compare CRT 
measurements differences between observers and 
P values less than 0.05 were considered statistically 
significant. 
For the analysis of the distribution of variables, we 
used the method fit Y by X. This method evaluates 
the relationship between variables. Thus, we found 
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the degree of agreement between the HT1-HT2 
(intraobserver) and HT1-ML3, HT2-LM3 
(interobserver) in 500 images of eyes of 500 
patients (one eye per person). 
 
2.18 Description of activities 
 
Description of activities 
 
       
Months 
 
Activities     
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
1
0 
 
1
1 
 
1
2 
 
1
3 
 
1
4 
 
1
5 
Selection 
of 
photograp
hs 
 
X 
 
X 
 
X 
            
Measurem
ent of 
CRT and 
V by HT 
   
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
 
 
 
     
Measurem
ent of 
CRT and 
V by ML 
      
 
   
X 
 
X 
 
 
 
 
   
Capture 
results in 
database 
           
X 
 
 
 
 
 
 
 
Analysis 
of results 
           
X 
 
X 
 
X 
 
 
 
Write 
results 
           X X X X 
 
*CRT= Central retinal thickness. *V= variables. 
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3. Results 
 
3.1 Demographic data 
For this study, we selected the images of the 
patients who met the inclusion and exclusion criteria 
of the Eberhard-Karls, Universitäts-Augenklinik, 
Tübingen. For the patients, we retrospectively 
reviewed the files of 500 eyes of 500 consecutive 
patients (one eye per person) who were examined 
between August 2009 and September 2012 and 
were diagnosed as having neovascular ARMD, 
BRVO, CRVO, DME and ERM.  
The demographic analysis was conducted based on 
the number of patients. 274 were male and 226 
female, the left eyes in 253 patients were included, 
while the right eyes were from 247 patients. The 
mean age was 73.2 years. (RANGE, 68 to 79) 
(Table 1). 
 
 
Eyes, n (%) 
 
 
 
Right 247 (49.4) 
Left 253 (50.6) 
Total 500 (100) 
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Gender, n (%) 
 
 
 
Men 274 (54.8) 
Women 226 (45.2) 
Age (y)  
                         Mean ± SD 73.2 ± 10.5 
                         Range 68-79 
Table 1. Demographics data of patients with macular diseases.  
n= Number of patients. 
 
Of the 500 images, a second selection was 
performed. 307 images were included in the study 
of CRT and 193 were discarded due to lack of 
concordance between observers (Table 2). 
DIAGNOSIS N HT1-
HT2 
HT1-
ML3 
HT2-
ML3 
HT1-
HT2-
ML3 
ARMD 100 82 73 74 72 
BRVO 100 87 54 55 54 
CRVO 100 81 55 57 55 
DME 100 91 53 55 53 
ERM 100 92 74 76 73 
Total 500 433 309 317 307 
Total % 100 % 86.6 % 61.8 % 63.4 % 61.4 % 
Table 2. Gradability of OCT-images by observers. 
* Imaging was assessed by both observers in 3 examinations. 
HT1= First examination by HT, HT2= Second examination by HT, 
ML3= First examination by ML. ARMD= Age-related macular 
degeneration, BRVO= Branch retinal vein occlusion, CRVO= Central 
retinal vein occlusion, DME= Diabetic macular edema, ERM= 
Epiretinal membrane, n= Number of patients. 
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3.2 Results of CRT in macular diseases 
A simple graphical method for assessing the 
agreement between two measurement systems was 
proposed by Bland and Altman. This method was 
used to analyze the difference between two 
measurements against their mean. (Altman DG, Bland 
JM, 1983; Bland JM, Altman DG, 1986). Therefore, to 
measure the CRT of each disease, the average 
values of the vertical line scanning and horizontal 
line scanning by HT (general ophthalmologist) and 
ML (retina specialist) were used respectively. After 
having been obtained, the 307 images, each 
diagnosis was analyzed separately by both 
observers. 
 
3.3 Intraobserver agreement in macular diseases 
(HT1-HT2). 
According to the intraobserver analysis between 
HT1 and HT2 the mean differences of the CRT were 
very similar, resulting in 1.67 to 9.50µm. The 
coefficient correlation (CC) was 0.73 to 0.98. The 
95% confidence interval (CI) was in ARMD (13.24; -
18.87 µm); BRVO (22.38;-3.25 µm); CRVO (33.53; -
19.89 µm); DME (11.29; -7.94 µm); ERM (29.48;-
23.34 µm); and the P-value of all of them was 
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greater than 0.05 statistically insignificant (Table 3) 
(Graphic 1). 
Therefore no significant differences were observed 
within 3 months by HT.  
Diagnosis n Mean 
CRT 
HT1 
(µm) 
Mean 
CRT 
HT2 
(µm) 
Mean 
Difference 
(µm) 
Correlation 
(CC) 
95 
% 
(CI)     
(µm) 
*P-value 
(P>0.05) 
ARMD 72 230.99 228.18 2.81 0.79 13,-
18 
O.72 
BRVO 54 347.97 338.40 9.56 0.95 22, -
3 
0.14 
CRVO 55 598.22 591.40 6.81 0.93 33, -
19 
0.61 
DME 53 408.38 406.70 1.67 0.98 11, -
7 
0.72 
ERM 73 293.24 290.17 3.06 0.73 29, -
23 
0.81 
Table 3. Intraobserver agreement in macular diseases. 
HT1= First examination by HT, HT2= Second examination by HT. 
ARMD= Age-related macular degeneration, BRVO= Branch retinal 
vein occlusion, CRVO= Central retinal vein occlusion, DME= Diabetic 
macular edema, ERM= Epiretinal membrane, n= Number of patients. 
CC= Coefficient correlation, CI= Confidence interval, µm= Microns. 
*P: paired t tests of mean CRT measurements between 
Intraobserver. 
 
3.4 Interobserver agreement in macular 
diseases: first analysis (HT1-ML3) 
In the interobserver analysis 307 images were 
analyzed by HT1 and ML3, obtaining a mean 
difference ranged from 1.88 to 32.27 µm. The CC 
between the two observers ranged from 0.74 to 
0.97. The 95% CI was in ARMD (17.24; -21.00 µm); 
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BRVO (43.62; 8.76 µm); CRVO (36.23; -13.27 µm); 
DME (27.25; 2.38 µm); ERM (50.34; 14.19 µm); and 
the P-value was statistically significant for DME 
(P<0.02), BRVO (P<0.004) and ERM (P<0.0007) 
but not in ARMD (P=0.84) and CRVO (P=0.35) 
(Table 4) (Graphic 2). 
Diagnosis n Mean 
CRT 
HT1 
(µm) 
Mean 
CRT 
ML3 
(µm) 
Mean 
Difference 
(µm) 
Correlation 
(CC) 
95 
% 
(CI) 
(µm) 
*P-value 
(P>0.05) 
ARMD 72 230.99 232.87 1.88 0.74 17, -
21 
O.84 
BRVO 54 347.97 321.78 26.19 0.91 43, 
8 
0.004 
CRVO 55 598.22 586.74 11.48 0.94 36, -
13 
0.35 
DME 53 408.38 393.56 14.81 0.97 27, 
2 
0.02 
ERM 73 293.24 260.97 32.27 0.82 50, 
14 
0.0007 
Table 4. Interobserver agreement in macular diseases: first analysis.  
HT1= First examination by HT, ML3= First examination by ML. 
ARMD= Age-related macular degeneration, BRVO= Branch retinal 
vein occlusion, CRVO= Central retinal vein occlusion, DME= Diabetic 
macular edema, ERM= Epiretinal membrane, n= Number of patients. 
CC= Coefficient correlation, CI= Confidence interval, µm= Microns. 
*P:  paired t tests of mean CRT measurements between 
Interobserver. 
 
 
3.5 Interobserver agreement in macular 
diseases: second analysis (HT2-ML3) 
In Bland-Altman analysis, interobserver mean 
difference ranged from 4.66 to 29.20 µm and CC 
ranged from 0.67 to 0.97. The 95% CI was in ARMD 
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(5.49; -14.82 µm); BRVO (31.69; 1.56 µm); CRVO 
(20.40; -11.08 µm); DME (28.23; -1.95 µm); ERM 
(55.19; 3.21 µm). An analysis of variance used for 
repeated measurement was statistically significant 
for BRVO (P<0.03) and ERM (P<0.02) but did not 
show significant difference in ARMD (P=0.36), 
CRVO (P=0.55), and DME (P=0.08).  
Therefore we can determine which of the five 
macular diseases had an agreement. These were 
ARMD, BRVO and DME but not CRVO, and ERM 
between observers (Table 5) (Graphic 3). 
Diagnosis n Mean 
CRT 
HT2 
(µm) 
Mean 
CRT 
ML3 
(µm) 
Mean 
Difference 
(µm) 
Correlation 
(CC) 
95 
% 
(CI) 
(µm) 
*P-value 
(P>0.05) 
ARMD 72 228.18 232.87 4.69 0.93 5, -
14 
O.36 
BRVO 54 338.40 321.78 16.62 0.93 31, 
1 
0.03 
CRVO 55 591.40 586.74 4.66 0.97 20, -
11 
0.55 
DME 53 406.70 393.56 13.13 0.95 28, -
1 
0.08 
ERM 73 290.17 260.97 29.20 0.67 55, 
3 
0.02 
Table 5. Interobserver agreement in macular diseases: second 
analysis. 
HT1= First examination by HT, ML3= First examination by ML. 
ARMD= Age-related macular degeneration, BRVO= Branch retinal 
vein occlusion, CRVO= Central retinal vein occlusion, DME= Diabetic 
macular edema, ERM= Epiretinal membrane, n= Number of patients. 
CC= Coefficient correlation, CI= Confidence interval, µm= Microns. 
*P:  paired t tests of mean CRT measurements between 
Interobserver. 
 
 
 
  
 
76 
 
ARMD   BRVO   CRVO 
 
Mean difference= 2.81 µm  Mean difference= 9.56 µm             Mean difference = 6.81 µm 
95% CI= 13.24; -18.87 µm  95% CI= 22.38;-3.25 µm              95% CI= 33.53; -19.89 µm 
 
 DME   ERM 
 
  Mean difference = 1.67 µm          Mean difference = 3.06 µm 
  95% CI= 11.29; -7.94 µm           95% CI= 29.48;-23.34 µm 
 
Graphic 1: Central retinal thickness between intraobserver in macular 
diseases.  
Bland-Altman analysis showing the degree of agreement between 
intraobserver (HT1-HT2) in 5 different macular diseases. 95% CI= 
Confidence interval, CRT= Central retinal thickness, ARMD= Age-
related macular degeneration, BRVO= Branch retinal vein occlusion, 
CRVO= Central retinal vein occlusion, DME= Diabetic macular 
edema, ERM= Epiretinal membrane, HT1= First examination by HT, 
HT2= Second examination by HT. 
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ARMD   BRVO   CRVO 
   
Mean difference = 1.88 µm  Mean difference = 26.19 µm                 Mean difference = 11.48 µm 
95% CI= 17.24; -21.00 µm    95% CI= 43.62; 8.76 µm                   95% CI= 36.23; -13.27 µm 
 
DME   ERM 
 
Mean difference = 14.81 µm  Mean difference = 32.27 µm 
95% CI= 27.25; 2.38 µm  95% CI= 50.34; 14.19 µm 
 
 
Graphic 2. Central retinal thickness between interobserver in macular 
diseases. 
Bland-Altman analysis showing the degree of agreement between 
interobserver (HT1-ML3) in 5 different macular diseases. 95% CI= 
Confidence interval, CRT= Central retinal thickness, ARMD= Age-
related macular degeneration, BRVO= Branch retinal vein occlusion, 
CRVO= Central retinal vein occlusion, DME= Diabetic macular 
edema, ERM= Epiretinal membrane, HT1= First examination by HT, 
ML3= First examination by ML. 
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ARMD   BRVO    CRVO 
 
       Mean Difference= 4.69 µm  Mean Difference= 16.62 µm          Mean Difference= 4.66 µm 
         95% CI= 5.49; -14.82 µm  95% CI= 31.69; 1.56 µm           95% CI= 20.40; -11.08 µm 
 
DME   ERM 
 
Mean Difference= 13.13 µm              Mean Difference= 29.20 µm 
95% CI= 28.23; -1.95 µm              95% CI= 55.19; 3.21 µm 
 
Graphic 3. Central retinal thickness between interobserver in macular 
diseases.   
Bland-Altman analysis showing the degree of agreement between 
interobserver (HT1-ML3) in 5 different macular diseases. 95% CI= 
Confidence interval, CRT= Central retinal thickness, ARMD= Age-
related macular degeneration, BRVO= Branch retinal vein occlusion, 
CRVO= Central retinal vein occlusion, DME= Diabetic macular 
edema, ERM= Epiretinal membrane, HT2= Second examination by 
HT, ML3= First examination by ML. 
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3.6 Results of morphological findings (variables)  
For the analysis of the distribution of variables, we 
used the method fit Y by X because this method 
evaluates the relationship between two variables. In 
this method we found the degree of agreement of 
13 morphological findings between HT1-HT2 
(intraobserver) and HT1-ML3, HT2-LM3 
(interobserver) in 500 images of eyes of 500 
patients (one eye per person) (Tables 6 to 18). 
 
   
     a- Agreement (HT1-HT2): 78.4%          b- Agreement (HT1-ML3): 55.2%     c- Agreement (HT2-ML3): 57.8% 
Table 6. Result of Foveal depression (Fo_De). 
Spectralis OCT findings: Fo_De1= Foveal depression analyzed by HT (first 
examination), Fo_De2= Foveal depression analyzed by HT (second 
examination), Fo_De3= Foveal depression analyzed by ML. 0- Foveal 
depression was normal, 1-Foveal depression was abnormal, 2- Foveal 
depression was not assessable. Red= Agreement, Blue=Not Agreement, 
Purple= Nongradable OCT Image.  
 
 
 
a- Agreement (HT1-HT2): 82.2%             b- Agreement (HT1-ML3): 45.2%     c- Agreement (HT2-ML3): 38.6% 
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Table 7. Result of Epiretinal membrane (ERM). 
Spectralis OCT findings: ERM 1= Epiretinal membrane analyzed by HT (first 
examination), ERM 2= Epiretinal membrane analyzed by HT (second 
examination), ERM 3= Epiretinal membrane analyzed by ML. 0-ERM not 
found, 1- ERM found, 2- ERM not assessable. Red= Agreement, Blue=Not 
Agreement, Purple=Nongradable OCT Image. 
 
 
a- Agreement (HT1-HT2): 92%               b- Agreement (HT1-ML3): 74.6%     c- Agreement (HT2-ML3): 74% 
Table 8. Result of Vitreofoveal traction (VFT). 
Spectralis OCT findings: VFT1= Vitreofoveolar traction by HT (first 
examination), VFT 2= Vitreofoveolar traction analyzed by HT (second 
examination), VFT 3= Vitreofoveolar traction analyzed by ML. 0-VFT not 
found, 1- VFT found, 2- VFT not assessable. Red= Agreement, Blue=Not 
Agreement, Purple= Nongradable OCT Image. 
 
  
 
a- Agreement (HT1-HT2): 85%              b- Agreement (HT1-ML3): 50.2%     c- Agreement (HT2-ML3): 48.6% 
Table 9. Result of Pseudocyst. 
Spectralis OCT findings: Pseudocyst 1= Analyzed by HT (first 
examination), Pseudocyst 2= Analyzed by HT (second examination), 
Pseudocyst 3=Analyzed by ML. 0- Pseudocyst not found, 1- 
Pseudocyst found, 2- Pseudocyst not assessable. Red= Agreement, 
Blue=Not Agreement, Purple= Nongradable OCT Image. 
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a- Agreement (HT1-HT2): 93.6%            b- Agreement (HT1-ML3): 69.4%     c- Agreement (HT2-ML3): 68% 
Table 10. Result of Splitting. 
Spectralis OCT findings: Splitting 1= Analyzed by HT (first 
examination), Splitting 2= Analyzed by HT (second examination), 
Splitting 3=Analyzed by ML. 0- Splitting not found, 1- Splitting found, 
2- Splitting not assessable. Red= Agreement, Blue=Not Agreement, 
Purple= Nongradable OCT Image. 
 
 
a- Agreement (HT1-HT2): 91.4%              b- Agreement (HT1-ML3): 72%     c- Agreement (HT2-ML3): 71.2% 
Table 11. Result of Verticalisation.  
Spectralis OCT findings: Verticalisation 1= Analyzed by HT (first 
examination), Verticalisation 2= Analyzed by HT (second 
examination), Verticalisation  3=Analyzed by ML. 0- Verticalisation 
not found, 1- Verticalisation found, 2- Verticalisation not assessable. 
Red= Agreement, Blue=Not Agreement, Purple= Nongradable OCT 
Image. 
 
a- Agreement (HT1-HT2): 94.2%               b- Agreement (HT1-ML3): 76%     c- Agreement (HT2-ML3): 74.8% 
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Table 12. Result of Macular hole (MH). 
Spectralis OCT findings: MH1= Macular hole analyzed by HT (first 
examination), MH2= Macular hole analyzed by HT (second 
examination), MH3= Macular hole analyzed by ML. 0- Macular hole 
not found, 1- Macular hole found, 2- Macular hole not assessable. 
Red= Agreement, Blue=Not Agreement, Purple= Nongradable OCT 
Image. 
 
 
a- Agreement (HT1-HT2): 89%                 b- Agreement (HT1-ML3): 71.8%     c- Agreement (HT2-ML3): 71.8% 
Table 13. Result of Pseudomacular hole (PSM). 
Spectralis OCT findings: PSM 1= Pseudomacular hole analyzed by 
HT (first examination), PSM 2= Pseudomacular hole analyzed by HT 
(second examination), PSM 3= Pseudomacular hole analyzed by ML. 
0- Pseudomacular hole not found, 1- Pseudomacular hole found, 2- 
Pseudomacular hole not assessable. Red= Agreement, Blue=Not 
Agreement, Purple= Nongradable OCT Image. 
 
 
a- Agreement (HT1-HT2): 92.2%              b- Agreement (HT1-ML3): 73.2%     c- Agreement (HT2-ML3): 72.2% 
Table 14. Result of Lamellar macular hole (LMH). 
Spectralis OCT findings: LMH 1= Lamellar macular hole analyzed by 
HT (first examination), LMH 2= Lamellar macular hole analyzed by 
HT (second examination), LMH 3= Lamellar macular hole analyzed 
by ML. 0- Lamellar macular hole not found, 1- Lamellar macular hole 
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found, 2- Lamellar macular hole not assessable. Red= Agreement, 
Blue=Not Agreement, Purple= Nongradable OCT Image. 
 
 
a- Agreement (HT1-HT2): 82.2%             b- Agreement (HT1-ML3): 65.8%     c- Agreement (HT2-ML3): 64.4% 
Table 15. Result of Neurosensory detachment (NSD). 
Spectralis OCT findings: NSD 1= Neurosensory detachment analyzed 
by HT (first examination), NSD 2= Neurosensory detachment 
analyzed by HT (second examination), NSD 3= Neurosensory 
detachment analyzed by ML. 0- Neurosensory detachment not found, 
1- Neurosensory detachment found, 2- Neurosensory detachment not 
assessable. Red= Agreement, Blue=Not Agreement, Purple= 
Nongradable OCT Image. 
 
 
a- Agreement (HT1-HT2): 89.4%             b- Agreement (HT1-ML3): 68.4%     c- Agreement (HT2-ML3): 68.4% 
Table 16. Result of Pigment epithelium detachment (PED). 
Spectralis OCT findings: PED 1= Pigment epithelium detachment 
analyzed by HT (first examination), PED 2= Pigment epithelium 
detachment analyzed by HT (second examination), PED 3= Pigment 
epithelium detachment analyzed by ML. 0- Pigment epithelium 
detachment not found, 1- Pigment epithelium detachment found, 2- 
Pigment epithelium detachment not assessable. Red= Agreement, 
Blue=Not Agreement, Purple= Nongradable OCT Image. 
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a- Agreement (HT1-HT2): 75.8%             b- Agreement (HT1-ML3): 47.2%     c- Agreement (HT2-ML3): 43.6% 
Table 17. Result of External limiting membrane (ELM).  
Spectralis OCT findings: ELM 1= External limiting membrane 
analyzed by HT (first examination), ELM 2= External limiting 
membrane analyzed by HT (second examination), ELM 3= External 
limiting membrane analyzed by ML. 0- ELM was normal, 1- ELM was 
abnormal, 2- ELM was not assessable. Red= Agreement, Blue=Not 
Agreement, Purple= Nongradable OCT Image.  
 
 
 
a- Agreement (HT1-HT2): 76.4%               b- Agreement (HT1-ML3): 52.8%     c- Agreement (HT2-ML3): 48.2% 
Table 18. Result of Photoreceptors inner and outer segments 
(IS/OS). 
Spectralis OCT findings: IS/OS 1= Photoreceptors inner and outer 
segments analyzed by HT (first examination), IS/OS 2= 
Photoreceptors inner and outer segments analyzed by HT (second 
examination), IS/OS 3= Photoreceptors inner and outer segments 
analyzed by ML. 0- IS/OS was normal, 1- IS/OS was abnormal, 2- 
IS/OS was not assessable. Red= Agreement, Blue=Not agreement, 
Purple= Nongradable OCT image.  
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3.7 Total results of morphological findings 
When analyzing the variables we found that the 
degree of agreement between HT1 and HT2 is 
above 379/500 (75.8%) of the images valued in 
ELM and up to 471/500 (94.2%) in MH. In the 
analysis between HT1 and ML3, the greater 
percentage of agreement occurred between images 
in patients with MH by 380 (76%) while the lowest 
agreement was observed in the images of ERM with 
226/500 (45.2%), obtaining a 37% decrease 
compared to HT1 and HT2 analysis.  
When analyzing the degree of agreement between 
HT2 and ML3, we found that the greatest degree of 
agreement was observed also in MH, with 374/500 
(74.8%), while in ERM the results obtained were 
very low with only 193/500 (38.6%). 
Therefore, a decrease was observed in the degree 
of intraobserver agreement from 86.30% to 63.21% 
and 61.66% of the interobserver (Table 19). 
 
 
 
 
  
 
86 
                       HT1-HT2           HT1-ML3           HT2-ML3 
VARIABLES N (%) N (%) n (%) 
FO_DE 392 (78.4) 277 (55.2) 299 (57.8) 
ERM 411 (82.2) 226 (45.2) 193 (38.6) 
VFT 460 (92) 373 (74.6) 370 (74) 
Pseudocyst 425 (85) 251 (50.2) 243 (48.6) 
Splitting 468 (93.6) 347 (69.4) 340 (68) 
Verticalisation 457 (91.4) 360 (72) 356 (71.2) 
MH 471 (94.2) 380 (76) 374 (74.8) 
PSM 448 (89.6) 359 (71.8) 359 (71.8) 
LMH 461 (92.2) 366 (73.2) 361 (72.2) 
NSD 411 (82.2) 329 (65.8) 322 (64.4) 
PED 447 (89.4) 342 (68.4) 342 (68.4) 
ELM 379 (75.8) 236 (47.2) 218 (43.6) 
IS/OS 382 (76.4) 264 (52.8) 241 (48.2) 
TOTAL  86.30%  63.21%  61.66% 
Table 19. Degree of agreement in morphological findings. 
Percentage of variables with greater agreement in 500 patients with 
macular diseases. HT1= First exploration by HT, HT2=Second 
exploration by HT, ML3=First examination by ML. MH=Macular hole, 
LMH=Lamellar macular hole, VFT=Vitreofoveolar traction, 
PSM=Pseudomacular hole, PED=Pigment epithelium detachment, 
NSD=Neurosensory detachment, ERM=Epiretinal membrane, 
Fo_De=Foveal depression, IS/OS=Photoreceptors inner and outer 
segments, ELM=External limiting membrane. 
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3.8 Results of nongradable morphological 
findings 
Percentages of nongradable is used to display 
which is the most difficult morphological finding to 
detect an image of Spectralis OCT. ELM was the 
feature most discarded with 175/500 (35%) by ML3, 
while MH and foveal depression was the variable 
most excluded by HT with 45/500 (9%) respectively. 
Also we can observe that images not valued 
(nongradable) among the first scan and the second 
scan were very identical, between 8 and 9% by HT 
whereas by ML3 had an increment more than 15% 
in all of them. 
Therefore, we found that the retina specialist ruled 
out a greater number of images 24.52% than 
general ophthalmologist 8.83% (Table 20). 
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                       HT1               HT2 ML3 
Variables N (%) N (%) n (%) 
FoDe 45 (9) 42 (8.4) 108 (21.6) 
ERM 44 (8.8) 42 (8.4) 114 (22.8) 
VFT 44 (8.8) 42 (8.4) 108 (21.6) 
Pseudocyst 44 (8.8) 42 (8.4) 112 (22.4) 
Splitting 44 (8.8) 42 (8.4) 125 (25) 
Verticalisation 44 (8.8) 42 (8.4) 107 (21.4) 
MH 45 (9) 42 (8.4) 107 (21.4) 
PSM 44 (8.8) 42 (8.4) 107 (21.4) 
LMH 44 (8.8) 42 (8.4) 107 (21.4) 
NSD 44 (8.8) 42 (8.4) 129 (25.8) 
PED 44 (8.8) 42 (8.4) 122 (24.4) 
ELM 44 (8.8) 42 (8.4) 175 (35) 
IS/OS 44 (8.8) 42 (8.4) 173 (34.6) 
Total      8.83 
% 
 8.40 %  24.52 % 
Table 20. Nongradable morphological findings. 
Percentage of variables more images not valued in 500 patients with 
macular diseases. HT1= First exploration by HT, HT2=Second 
exploration by HT, ML3=First exploration by ML. MH=Macular hole, 
LMH=Lamellar macular hole, VFT=Vitreofoveolar traction, 
PSM=Pseudomacular hole, PED=Pigment epithelium detachment, 
NSD=Neurosensory detachment, ERM=Epiretinal membrane, 
Fo_De=Foveal depression, IS/OS=Photoreceptors inner and outer 
segments, ELM=External limiting membrane, n= Number of patients. 
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4. Discussion 
In the last decade, OCT has emerged as a useful 
and adjunctive imaging technique, providing high-
resolution cross-sectional images and valuable 
information about various pathologic features of the 
macula (Huang D, Swanson EA, Lin CP et al. 1991; Puliafito CA, 
Hee MR, Lin CP et al.1995). Quantification of macular 
thickness by OCT in a reproducible, non-invasive 
way allows clinicians to monitor the efficacy of 
treatment for macular pathologic features like 
diabetic macular edema (Lam DS, Chan CK, et al. 2007; 
Chew E, Strauber S, et al. 2007).  
Spectral-domain OCT has revolutionized the 
diagnostic and examination in a number of 
vitreoretinal conditions like macular edema (ME) 
associated with vascular occlusions, diabetic 
retinopathy, ARMD and vitreoretinal interface 
disorders. (Forooghian F, et al 2008; Yamaike N, et al. 2008; 
Fleckenstein M, et al. 2008). Also provides a higher 
sensitivity to detect morphological changes that 
occur in the preretinal, intraretinal, subretinal and 
sub/RPE space; such as ERM, macular holes, 
accumulation of intraretinal fluid, pigment epithelium 
detachment and photoreceptor outer segment 
disruption (Keane PA, Bhatti RA, 2009). 
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However, even though the revolutionary 
improvement in the imaging of the eye, some 
difficulties become evident in the evaluating the 
obtained OCT images, The new spectral-domain 
OCT device provides special software showing the 
segmentation of the retinal layers. Consequently 
those positions are regulated automatically by the 
software of each instrument (Wolf-Schnurrbusch UE, Ceklic 
L, et al., 2009).  The identification of the artifacts of the 
images and falsely settled segmentation lines are 
important to avoid the errors created by the OCT 
devices (Ian C, Han, MD, Glenn J. Jaffe, MD, 2010). 
The second method for analyzing the OCT images 
is the manual measurement, where the observer 
marks, with the caliper, the areas of interest by 
using the software provided by the OCT-machine. 
Even though overcoming the segmentation errors 
created by the OCT-machine, subjectivity of this 
method is the major limitation (Wolf-Schnurrbusch UE, 
Ceklic L, et al., 2009).   
Our study was designed to analyze the 
concordance between a general ophthalmologist 
and a retina specialist in the interpretation of 
Spectralis OCT images obtained in five of the most 
common macular diseases ARMD, BRVO, CRVO, 
DME and ERM. 
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According to the intraobserver analysis obtained by 
the general ophthalmologist in two examinations 
(HT1-HT2), in each group of macular diseases the 
mean difference of CRT was not found to be 
statistically significant (Table 3). 
In the first interobserver analysis (HT1-ML3) of the 
CRT, a high degree of agreement in ARMD and 
CRVO was seen. ARMD was the disease with the 
lowest mean CRT (230.99µm by HT1 and 
232.87µm by ML3) while CRVO showed the highest 
mean CRT with (598.22 µm by HT1 and 586.74 µm 
by ML3). In contrast, other diseases such as BRVO 
(347.97 µm by HT1 and 321.78 µm by ML3), DME 
(408.38 µm by HT1 and 393.56 µm by ML3) and 
ERM (293.24 µm by HT1 and 260.97 µm by ML3), 
the disagreement was statistically significant 
(BRVO: P=0.004, DME: P=0.02, ERM: P=0.0007 
(Table 4).  
A possible explanation for these discrepancies 
could be the negative transfer of experience from 
the TD-OCT by the general ophthalmologist, since 
the inferior limit of the CRT measurements were 
tended to end (Fig. 34), at the IS/OS junction 
whereas the retina specialist included the outer 
boundary of RPE/Bruch membrane complex in the 
measurement by using the TD-OCT (Fig. 35). The 
general ophthalmologist measured from the internal 
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limiting membrane (ILM) and the junction of the 
outer and inner segment of the photoreceptors 
(IS/OS) whereas the retina specialist measured 
from the outer boundary includes the RPE/Bruch 
membrane complex. 
 
Fig. 34: Spectralis OCT vertical line scan shows CRT measurement 
of 434 µm from ILM (green arrow) to the junction of the IS/OS (red 
arrow) by the general ophthalmologist.  
 
Fig. 35: Spectralis OCT vertical line scan shows the correct CRT 
measurement (489µm) from ILM (green arrow) to RPE/Bruch 
membrane complex (yellow arrow) by the retina specialist.  
Previous studies have reported that SD-OCT and 
TD-OCT have a significant difference in measuring 
the boundaries of CRT (Han IC, Jaffe G, 2008; Grover S et al. 
2009; Giani A et al. 2010; Piero L et al. 2010). TD-OCT 
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generated segmentation system uses the IS/OS 
hyper-reflective band for boundary in the 
measurement of the CRT. The new SD-OCT system 
is capable to show in the outer retinal layers three 
distinct hyper-reflective bands. The bands 
correspond to the ELM, IS/OS and the RPE.  
The SOCT Copernicus, Spectral OCT/SLO, RTvue-
100 and 3D OCT-1000 use the second inner hyper-
reflective band as the outer border of the retina. 
Cirrus HD-OCT and Spectralis HRA+OCT identify 
the external reflective band as the outer border 
RPE/Bruch’s membrane complex if automatically 
generated segmentation protocol is chosen. (Wolf-
Schnurrbusch UE, Ceklic L, et al., 2009).  
In the second interobserver analysis (HT2-ML3) of 
the mean CRT considering all the five diseases, the 
mean difference of the CRT ranged from (4.66 to 
29.20 µm); the disagreement was a statistically 
significant in BRVO (P < 0.03) and ERM (P < 0.02) 
but not for ARMD, CRVO and DME. The CRT 
measurements in ARMD, CRVO and DME were 
within the agreement limits. However in BRVO (P < 
0.03) and ERM (P < 0.02) statistically significant 
interobserver disagreement was found. These 
results can be interpreted as a positive effect of the 
learning curve of the general ophthalmologist in the 
second analysis (Table 5). 
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The intra- and interobserver agreement in 
identifying the predetermined morphological findings 
in the macula was analyzed, which are seen in the 
selected five different diseases. Of the 13 
morphological findings, the average agreement for 
detection of all features in this study was 86.30% for 
HT1 vs HT2 (intraobserver), 63.21% for HT1 vs. ML 
(interobserver 1) and 61.66% for HT2 vs ML 
(interobserver 2).  
We note that the highest degree of agreement 
between the two observers was in the intraretinal 
layers (MH, LMH, PSM, verticalisation, splitting); 
MH was the feature with the highest degree of 
agreement of 78.4%, while the lowest degree of 
agreement was ERM in the preretinal space with 
38.6%, followed by subretinal features ELM and IS 
/OS with 43.6% and 48.2% respectively (Table 19).  
According to Keane PA and associates, SD-OCT 
has a high sensitivity and high resolution to 
distinguish and detect relevant morphological 
changes in the preretinal space (e.g. ERM and 
VMT) as well as MH and fine structures of the 
subretinal space (Keane PA et al., 2009). Also Knecht PB 
and associates, have mentioned that the Spectralis 
OCT had a good degree of agreement between 
observers to detect ERM and pseudocyst and a low 
level of agreement for detecting subretinal 
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morphological changes as ELM and IS/ OS (Knecht 
PB et al., 2013).  
In our study, we found that besides the high 
sensitivity and high resolution imaging by Spectralis 
OCT in detecting macular morphological findings, 
the interpretation of the findings were not free of 
bias, based mainly on the learning curve. 
Consequently, the therapy decisions may therefore 
show considerable differences in some eyes based 
on the experience of the observer.  
By analyzing the nongradable OCT-images of the 
morphological findings, we observed no significant 
difference in all the variables by the general 
ophthalmologist (HT1: 8.83%, HT2: 8.4%) (Table 
20). In comparison with the retina specialist for the 
gradability revealed a significant disagreement in all 
the variables ML3: 24.52%.  ELM: 35% and IS/OS: 
34.6% the variables most discarded were by the 
retina specialist (Fig. 36).  
 
Fig. 36: Spectralis OCT vertical line scan shows an insufficient image 
quality of the macula for distinguish ELM and IS/OS (red arrow). This 
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image was decided as nongradable by the retina specialist. Note the 
poor saturation of the image. 
The detection of the ELM and IS/OS can offer 
difficulties, if the macular morphology is presented 
with additional changes in the pigment epithelium 
(Knecht PB et al., 2013). It was also mentioned that 
thanks to the high resolution of SD-OCT, in general, 
it is easier to detect morphological changes in 
preretinal and subretinal spaces than within the 
retina. Therefore, our results were probably due to 
the learning curve of the general ophthalmologist. 
 
The recent advances in the treatment of the 
frequently seen macular diseases, such as ARMD, 
BRVO, CRVO, DME and ERM lead to a 
considerable increase in the number of patients, 
with the need of active follow-up examinations in 
relatively short intervals. Currently, before any 
clinical decision for a treatment of a macular 
disease, an OCT examination is qua sine none. 
Even though the Spectralis OCT is a very useful tool 
in distinguishing and detecting morphological 
findings in various macular diseases, the captured 
images needs to be interpreted correctly. Our 
analysis was aimed to find the general agreement 
between a general ophthalmologist without any 
experience in interpreting the Spectralis OCT and a 
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retina specialist, trained in Spectralis OCT. For this 
analysis we chose five most common retinal 
diseases with macular affection. We found 
considerable interobserver disagreement in the 
decision for the gradability of the OCT images.    We 
also observed a tendency for improved 
interpretation of the general ophthalmologist in the 
second analysis. For the ARMD, CRVO and DME 
the interobserver agreement was in concordance 
(ARMD: 228.18 µm by HT2 and 232.87µm by ML3, 
P= 0.36; CRVO: 591.40 µm by HT2 and 586.74 µm 
by ML3, P= 0.55; and DME: 406.70 µm by HT2 and 
393.56 µm by ML3, P= 0.08).  However for some 
findings, such as (BRVO: 338.40 µm by HT2 and 
321.78 µm by ML3, P= 0.03; ERM: 290.17 µm by 
HT2 and 260.97 µm by ML3, P= 0.02) the decision 
made by the general ophthalmologist was not 
sufficient (disagreement statistical significant) 
(Table 5).  
In summary, in the fellowship period of the posterior 
segment diseases, the education program or 
inexperienced ophthalmologists should consider an 
intensive teaching period in interpreting OCT 
examinations.  
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5. Summary 
The macula is the center of the posterior pole, and 
responsible for high acuity vision which is important 
for facilities like reading, writing, driving and working 
on the computer. Macular edema (ME) is the most 
common pathology of the macula resulting in 
impairment of central vision. Diseases such as 
diabetic macular edema (DME), age-related 
macular degeneration (ARMD), retinal vascular 
occlusive diseases, and vitreoretinal interface 
disorders are the most frequent reasons of ME. 
Developments in pharmacotherapy provide effective 
treatment options for some macular diseases. ME 
presents with morphological findings in the 
preretinal, intraretinal and subretinal space. It is also 
associated with changes in the retinal pigment 
epithelium and choriocapillaris complex. 
Recent technological advances in the optical 
coherence tomography (OCT) have resulted in high-
resolution imaging of the macula and their 
morphological changes. Spectralis OCT has a scan 
speed of 40,000 A-scans per second with 7µm 
optical and 3.9µm digital axial resolution and is an 
effective tool in the detection, evaluation and 
monitoring of the central retinal thickness 
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measurement (CRT) and morphological retinal 
features in vitreoretinal disorders. 
It also became evident, that despite the 
improvement of the OCT-techniques, the 
measurements and interpretation of the macular 
morphology may vary according to several factors 
such as the type of the OCT machine, the quality of 
the captured images, the experience of the 
physician and lastly the complexity of the findings. 
Therefore we aimed to analyze the agreement 
between a general ophthalmologist (intraobserver) 
and a specialist of the retinal diseases 
(interobserver) in the OCT-examination of different 
macular diseases. The examination included the 
measurement of the CRT and the identification of 
morphological findings in 500 eyes of 500 patients. 
In total, 100 eyes of five different diseases (AMD, 
diabetic macular edema, branch retinal vein 
occlusion, central retinal vein occlusion and 
epiretinal membrane) were selected. 
The comparison between the first and second CRT-
measurement by the general ophthalmologist 
(intraobserver agreement) were statistically not 
significant. In other words, the CRT-measurements 
of the general ophthalmologist in the two 
consecutive sessions did not reveal a meaningful 
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difference considering the whole eyes and each 
separate disease. 
In the first interobserver analysis, the CRT-
measurements were in concordance in eyes having 
ARMD (P=0.84) and CRVO (P=0.35). In eyes with 
DME (P<0.02), BRVO (P<0.004) and ERM 
(P<0.0007), the comparison of the CRT-
measurements showed a poor agreement. 
The second interobserver analysis for the CRT-
measurements revealed a general improvement of 
the general ophthalmologists. In three diseases, 
ARMD (P=0.36), CRVO (P=0.55), and DME 
(P=0.08), the comparison did not show a statistical 
significance. The comparison in BRVO (P<0.03) 
and ERM (P<0.02) revealed a statistical significance 
between the measurement of the observers. 
In the analysis of the predetermined morphological 
findings, the highest agreement between the two 
observers was the identification of the features 
within the retinal layers, such as MH, LMH, PSM, 
verticalisation and splitting; MH was the feature with 
the highest agreement with 78.4%. Interestingly, the 
lowest agreement was ERM in the preretinal space 
with 38.6%, followed by subretinal features ELM 
and IS /OS with 43.6% and 48.2% respectively. 
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In summary, we found intraobserver and 
interobserver differences exist in analysis of the 
images taken by the Spectralis-OCT in several 
macular diseases. A training course of three months 
for the general ophthalmologist has resulted in 
improved interpretation of some morphological 
features in macula. However, based on the result of 
our study, a longer period with an intensive, 
interactive teaching program is needed for a general 
ophthalmologist for a reliable analysis of Spectralis-
OCT images in macular diseases. 
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7. Deutsche Zusammenfassung 
Die Makula stellt das Zentrum des hinteren Pols im 
Auge dar und ist mit ihrer hohen Ortsauflösung 
wichtig für Fähigkeiten wie Lesen, Schreiben, 
Fahren oder Computerarbeit. Das Makulaödem 
(MÖ) ist die häufigste Pathologie im Bereich der 
Makula und resultiert in einer eingeschränkten 
Sehschärfe. Erkrankungen wie das diabetische 
Makulaödem (DMÖ), die altersbedingte 
Makuladegeneration (ARMD), retinale 
Gefäßverschlüsse und Veränderungen im Bereich 
der vitreoretinalen Schichtgrenzen stellen die 
häufigsten Gründe für ein MÖ dar. Durch 
Entwicklungen in der Pharmakotherapie können nun 
effektive Behandlungsmöglichkeiten für einige 
Makula-Erkrankungen bereitgestellt werden. Das 
MÖ geht mit morphologischen Auffälligkeiten im 
prä-, intra- und subretinalen Raum einher. Es wird 
zudem von Veränderungen im retinalen 
Pigmentepithel und der Choriokapillaris begleitet. 
Bisherige technologische Fortschritte in der 
Optischen Kohärenz Tomographie (OCT) 
resultierten in hochauflösenden Bildern der Makula 
und erlauben die Darstellung morphologischer 
Veränderungen. Das Spectralis-OCT arbeitet mit 
einer Scangeschwindigkeit von 40.000 A-Scans pro 
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Sekunde bei einer axialen Auflösung von 7µm 
optisch bzw. 3,9µm digital. Es stellt somit ein 
effektives Hilfsmittel für die Detektion, Bewertung 
und Verlaufsbeurteilung von zentralen 
Retinadickenmessungen (CRT) und 
morphologischen Befunden in der Makula. 
Es ist bekannt, dass trotz der Verbesserung der 
OCT-Techniken, Messungen im Bereich der Makula 
und deren Interpretation durch verschiedene 
Faktoren beeinflusst und somit variieren können. Zu 
den Störgrößen gehören z.B. Geräte verschiedener 
Hersteller, die Qualität der aufgenommenen Bilder, 
die Erfahrung des Befunders und nicht zuletzt die 
Komplexität der Befunde. 
Unsere Ziele waren daher die Analyse der 
Übereinstimmung (intraobserver und interobserver) 
eines Allgemein-Augenarztes und eines erfahrenen 
Untersucher (Netzhaut-Spezialist) bei der 
Auswertung verschiedener Makulaveränderungen. 
Die Untersuchung umfasste die Messung der CRT 
und die Identifikation morphologischer 
Veränderungen in 500 Augen von 500 Patienten. 
Von der Gesamtzahl entfielen je 100 Augen auf fünf 
verschiedene Erkrankungen (altersbedingte 
Makuladegeneration, diabetisches Makulaödem, 
Venenastverschluss, Zentralvenenverschluss und 
epiretinale Membran). 
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Der Vergleich der ersten und zweiten CRT-Messung 
durch den Allgemein-Augenarztes (Intraobserver-
Übereinstimmung) war statistisch nicht signifikant. 
Deshalb lässt sich sagen, dass die CRT-Messungen 
des Allgemein- Augenarztes in den beiden 
aufeinander folgenden Serien zeigten keine 
wesentlichen Unterschiede sowohl in Bezug auf die 
gesamten Augen als auch in Bezug auf die 
einzelnen Erkrankungsbilder. 
Bei der ersten Interobserver-Analyse zeigten die 
CRT-Messungen bei Augen mit ARMD (P=0,81) 
und CRVO (P=0,35) eine gute Übereinstimmung. 
Bei Augen mit DME (P<0,02), BRVO (P<0,04) und 
ERM (P<0,0007) zeigte der Vergleich mit den CRT-
Messungen eine unzureichende Übereinstimmung. 
Die zweite Interobserver-Analyse für CRT-
Messungen zeigte eine generelle Verbesserung des 
Allgemein-Augenarztes. Bei drei Pathologien, 
ARMD (P=0,36), CRVO (P=0,55) und DME 
(P=0,08) zeigte der Vergleich keine statistische 
Signifikanz. Der Vergleich von BRVO (P<0,03) und 
ERM (P<0,02) deckte eine statistische Signifikanz 
zwischen den Messungen der Befunder auf. 
Bei der Auswertung vorgegebener morphologische 
Befunden konnte die höchste Übereinstimmung 
zwischen den Befundern bei der Identifikation von 
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Veränderungen innerhalb der Netzhautschichten 
wie z.B. MH, LMH, PSM, Vertikalisierung und 
Spaltung der Retina beobachtet werden. Die 
höchste Übereinstimmung war mit 78.4% bei der 
Diagnose des MH zu finden. Interessanterweise 
fand sich mit 38,6% die geringste Übereinstimmung 
bei ERM im präretinalen Raum, gefolgt von 
subretinalen Veränderungen im Bereich der ELM 
und der IS/OS- Schicht mit 43.6% bzw. 48.2%. 
Insgesamt konnten wir feststellen, dass Intra- und 
Interobserverunterschiede bei unterschiedlichen 
Makulapathologien bzw. deren Auswertung anhand 
von Bildbefunden des Spectralis-OCT bestehen. 
Eine Trainingszeit von drei Monaten resultierte in 
einer teilweise besseren Interpretationsfähigkeit 
Makula-Morphologien durch den Allgemein-
Augenarzt. 
Basierend auf unseren Untersuchungsergebnissen 
muss jedoch davon ausgegangen werden, dass 
eine längere Trainingszeit mit intensiviertem Lernen 
(z.B. mittels interaktiven Möglichkeiten) notwendig 
ist, um eine zuverlässige Analyse von Spectralis-
OCT-Bildern mit Makulaveränderungen durch den 
Allgemein-Augenarzt zu erreichen. 
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